View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2016	Mar. 20, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Avadel Pharmaceuticals PLC
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	AVDL
Entity Common Stock, Shares Outstanding		41,379,554
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2016
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 435,055,125

Consolidated Statements of Income (Loss) - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Product sales and services	$ 147,222,000	$ 172,288,000	$ 12,193,000
License and research revenue	3,024,000	721,000	2,782,000
Total	150,246,000	173,009,000	14,975,000
Operating expenses:
Cost of products and services sold	13,248,000	11,410,000	3,383,000
Research and development	34,611,000	25,608,000	17,298,000
Selling, general and administrative	44,179,000	21,712,000	15,698,000
Intangible asset amortization	13,888,000	12,564,000	11,749,000
Changes in fair value of related party contingent consideration	49,285,000	30,957,000	57,491,000
Loss on early repayment of related party acquisition-related note	0	0	3,013,000
Total	155,211,000	102,251,000	108,632,000
Operating income (loss)	(4,965,000)	70,758,000	(93,657,000)
Investment and other income	1,635,000	1,236,000	927,000
Interest expense	(963,000)	0	(5,747,000)
Other expense - changes in fair value of related party payable	(6,548,000)	(4,883,000)	(3,525,000)
Foreign exchange gain	1,123,000	10,594,000	11,871,000
Income (loss) before income taxes	(9,718,000)	77,705,000	(90,131,000)
Income tax provision (benefit)	31,558,000	35,907,000	(644,000)
Net income (loss) from continuing operations	(41,276,000)	41,798,000	(89,487,000)
Net income from discontinued operations	0	0	4,018,000
Net income (loss)	$ (41,276,000)	$ 41,798,000	$ (85,469,000)
Earnings (loss) per share - basic:
Continuing operations (in usd per share)	$ (1.00)	$ 1.03	$ (2.47)
Discontinued operations (in usd per share)	0.00	0.00	0.11
Net income (loss) (in usd per share)	(1.00)	1.03	(2.36)
Earnings (loss) per share - diluted:
Continuing operations (in usd per share)	(1.00)	0.96	(2.47)
Discontinued operations (in usd per share)	0.00	0.00	0.11
Net income (loss) (in usd per share)	$ (1.00)	$ 0.96	$ (2.36)
Earnings (loss) per share
Weighted average number of shares outstanding - basic (in shares)	41,248	40,580	36,214
Weighted average number of shares outstanding - diluted (in shares)	41,248	43,619	36,214

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (41,276)	$ 41,798	$ (85,469)
Other comprehensive income (loss), net of tax:
Foreign currency translation loss	(1,024)	(15,087)	(18,040)
Net other comprehensive income (loss) on marketable securities, net of $16, ($20), ($0) tax, respectively	116	(147)	(198)
Total other comprehensive loss, net of tax	(908)	(15,234)	(18,238)
Total comprehensive (loss) income	$ (42,184)	$ 26,564	$ (103,707)

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Unrealized gain (loss) on marketable securities, tax	$ 16	$ (20)	$ 0

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 39,215	$ 65,064
Marketable securities	114,980	79,738
Accounts receivable	17,839	7,487
Inventories	3,258	3,666
Research and development tax credit receivable	0	2,382
Prepaid expenses and other current assets	5,894	8,064
Total current assets	181,186	166,401
Property and equipment, net	3,320	2,616
Goodwill	18,491	18,491
Intangible assets, net	22,837	15,825
Research and development tax credit receivable	1,775	0
Income tax deferred charge	10,342	11,581
Other	7,531	167
Total assets	245,482	215,081
Current liabilities:
Current portion of long-term debt	268	434
Current portion of long-term related party payable	34,177	25,204
Accounts payable	7,105	5,048
Deferred revenue	2,223	5,121
Accrued expenses	17,222	9,308
Income taxes	1,200	0
Other	226	133
Total current liabilities	62,421	45,248
Long-term debt	547	684
Long-term related party payable	135,170	97,489
Other	5,275	2,526
Total liabilities	203,413	145,947
Shareholders' equity:
Preferred shares, $0.01 nominal value; 50,000 shares authorized at December 31, 2016, none authorized at December 31, 2015; none issued or outstanding at December 31, 2016 and December 31, 2015, respectively	0	0
Ordinary shares, nominal value of $0.01 and €0.122; 500,000 and 53,178 shares authorized; 41,371 and 41,241 issued and outstanding at December 31, 2016 and 2015, respectively	414	6,331
Additional paid-in capital	385,020	363,984
Accumulated deficit	(319,800)	(278,524)
Accumulated other comprehensive loss	(23,565)	(22,657)
Total shareholders' equity	42,069	69,134
Total liabilities and shareholders' equity	$ 245,482	$ 215,081

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2016 $ / shares shares	Dec. 31, 2015 € / shares shares	Dec. 31, 2015 $ / shares shares
Statement of Financial Position [Abstract]
Preferred shares, nominal value (in usd per share) \| $ / shares	$ 0.01		$ 0
Preferred shares, shares authorized (in shares)	50,000,000	0	0
Preferred shares, shares issued (in shares)	0	0	0
Preferred shares, shares outstanding (in shares)	0	0	0
Ordinary shares, nominal value (in usd or euro per share) \| (per share)	$ 0.01	€ 0.122
Ordinary shares, shares authorized (in shares)	500,000,000	53,178,000	53,178,000
Ordinary shares, shares issued (in shares)	41,371,000	41,241,000	41,241,000
Ordinary shares, shares outstanding (in shares)	41,371,000	41,241,000	41,241,000

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Ordinary Shares	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2013	$ (8,819)	$ 3,746	$ 211,473	$ (234,853)	$ 10,815
Balance (in shares) at Dec. 31, 2013		25,613
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(85,469)			(85,469)
Other comprehensive loss	(18,238)				(18,238)
Subscription of warrants	351		351
Exercise of stock options or warrants	6,025	$ 164	5,861
Exercise of stock options or warrants (in shares)		1,001
Vesting of free shares	0	$ 24	(24)
Vesting of free shares (in shares)		151
Stock-based compensation expense	2,894		2,894
Public offering	115,232	$ 2,099	113,133
Public offering (in shares)		12,400
Shares granted to Recipharm AB	13,049	$ 155	12,894
Shares granted to Recipharm AB (in shares)		1,026
Ending balance at Dec. 31, 2014	25,025	$ 6,188	346,582	(320,322)	(7,423)
Balance (in shares) at Dec. 31, 2014		40,191
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	41,798			41,798
Other comprehensive loss	(15,234)				(15,234)
Subscription of warrants	601		601
Exercise of stock options or warrants	6,389	$ 123	6,266
Exercise of stock options or warrants (in shares)		899
Vesting of free shares	0	$ 20	(20)
Vesting of free shares (in shares)		151
Stock-based compensation expense	7,741		7,741
Excess tax benefit from stock-based compensation	2,814		2,814
Ending balance at Dec. 31, 2015	69,134	$ 6,331	363,984	(278,524)	(22,657)
Balance (in shares) at Dec. 31, 2015		41,241
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(41,276)			(41,276)
Other comprehensive loss	(908)				(908)
Subscription of warrants	326		326
Exercise of stock options or warrants	114	$ 2	112
Exercise of stock options or warrants (in shares)		15
Vesting of free shares	0	$ 18	(18)
Vesting of free shares (in shares)		115
Stock-based compensation expense	14,679		14,679
Cross-border merger nominal value adjustment	0	$ (5,937)	5,937
Ending balance at Dec. 31, 2016	$ 42,069	$ 414	$ 385,020	$ (319,800)	$ (23,565)
Balance (in shares) at Dec. 31, 2016		41,371

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income (loss)	$ (41,276)	$ 41,798	$ (85,469)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	14,489	13,132	14,141
Loss (gain) on disposal of property and equipment	110	0	(4,952)
Loss on sale of marketable securities	826	779	0
Unrealized foreign currency exchange gain	(349)	(8,969)	(6,252)
Gains on waiver of research and development grants and other	0	(1,498)	(589)
Remeasurement of related party acquisition-related contingent consideration	49,285	30,957	60,503
Remeasurement of related party financing-related royalty agreements	6,548	4,883	3,319
Change in deferred tax and income tax deferred charge	(4,000)	69	(2,113)
Stock-based compensation expense	14,679	7,741	2,690
Increase (decrease) in cash from:
Accounts receivable	(10,050)	(8,440)	3,249
Inventories	1,831	3,036	(3,112)
Prepaid expenses and other current assets	3,412	(684)	(2,329)
Research and development tax credit receivable	397	2,975	13,210
Accounts payable & other current liabilities	(434)	(8,533)	7,219
Deferred revenue	(2,923)	3,815	(55)
Accrued expenses	6,764	3,376	452
Accrued income taxes	1,778	(393)	70
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(20,252)	0	0
Royalty payments for related party payable in excess of original fair value	(2,469)	0	0
Other long-term assets and liabilities	535	249	(10,599)
Net cash provided by (used in) operating activities	18,901	84,293	(10,617)
Cash flows from investing activities:
Purchases of property and equipment	(1,201)	(1,629)	(1,728)
Proceeds from disposal of property and equipment	0	0	13,242
Acquisitions of businesses, including cash acquired and other adjustments	628	0	0
Proceeds from sales of marketable securities	71,546	48,308	24,993
Purchases of marketable securities	(107,603)	(78,409)	(79,590)
Net cash used in investing activities	(36,630)	(31,730)	(43,083)
Cash flows from financing activities:
Reimbursement of loans	0	(4,911)	(34,186)
Reimbursement of conditional R&D grants	(277)	(747)	(355)
Principal payments on capital lease obligations	0	0	(161)
Earn-out payments for related party contingent consideration	(6,892)	(24,526)	(1,357)
Royalty payments for related party payable	(1,225)	(3,371)	(206)
Excess tax benefit from stock-based compensation	0	2,814	0
Cash proceeds from issuance of ordinary shares and warrants	440	6,990	132,260
Net cash provided by (used in) financing activities	(7,954)	(23,751)	95,995
Effect of exchange rate changes on cash and cash equivalents	(166)	(3,508)	(9,171)
Net increase (decrease) in cash and cash equivalents	(25,849)	25,304	33,124
Cash and cash equivalents at January 1	65,064	39,760	6,636
Cash and cash equivalents at December 31	39,215	65,064	39,760
Supplemental disclosures of cash flow information:
Income tax paid	27,180	42,121	403
Interest paid	$ 788	$ 4,738	$ 4,431

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Nature of Operations. Avadel Pharmaceuticals PLC (“Avadel,” the “Company,” “we,” “our,” or “us”) is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies:

•

the development of differentiated, patent protected products through application of the Company’s proprietary patented drug delivery platforms, Micropump® and LiquiTime®, that target high-value solid and liquid oral and alternative dosages forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn’t depend on efficacy, safety, and toxicity data created by the sponsor. In addition to Micropump® and LiquiTime®, the Company has two other proprietary drug delivery platforms, Medusa™ (hydrogel depot technology for use with large molecules and peptides) and Trigger Lock™ (controlled release of opioid analgesics with potential abuse deterrent properties).

•

the identification of Unapproved Marketed Drugs (“UMDs”), which are currently sold in the U.S., but unapproved by the FDA, and the pursuit of approval for these products via a 505(b)(2) New Drug Application (NDA). To date, the Company has received approvals through this “unapproved-to-approved” avenue for three products: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). As a potential source of near-term revenue growth, Avadel is working on the development of a fourth product for potential NDA submission by year-end 2017, and seeks to identify additional product candidates for development with this strategy.

•

the acquisition of commercial and or late-stage products or businesses. The Company markets three branded pediatric-focused pharmaceutical products in the primary care space, and a 510(k) approved device that will launch in the second quarter of 2017, all of which were purchased through the acquisition of FSC Laboratories and FSC Pediatrics on February 5, 2016. We will consider further acquisitions, and the Company continues to look for assets that could fit strategically into its current or potential future commercial sales force.

The Company was incorporated in Ireland on December 1, 2015 as a private limited company, and re-registered as an Irish public limited company on November 21, 2016. Its headquarters are in Dublin, Ireland and it has operations in St. Louis, Missouri, United States, and Lyon, France.

The Company is an Irish public limited company, or plc, and is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the merger of Flamel with and into the Company which was completed at 11:59:59 p.m., Central Europe Time, on December 31, 2016 (the “Merger”) pursuant to the agreement between Flamel and Avadel entitled Common Draft Terms of Cross-Border Merger dated as of June 29, 2016 (the “Merger Agreement”). Immediately prior to the Merger, the Company was a wholly owned subsidiary of Flamel. As a result of the Merger Agreement:


•	Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel.


•	our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each


◦	all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital

◦

our board of directors is authorized to issue preferred shares on a non-pre-emptive basis, for a maximum period of five years, at which point it may be renewed by shareholders. The board of directors has discretion to dictate terms attached to the preferred shares, including voting, dividend, conversion rights, and priority relative to other classes of shares with respect to dividends and upon a liquidation.


•	all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company.

Thus, the Merger changed the jurisdiction of our incorporation from France to Ireland, and an ordinary share of the Company held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger.

References in these consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” "our," “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires.

Prior to completion of the Merger, the Flamel ADSs were listed on the Nasdaq Global Market (“Nasdaq”) under the trading symbol “FLML”; and immediately after the Merger the Company’s ADSs were listed for and began trading on Nasdaq on January 3, 2017 under the trading symbol “AVDL.”

Further details about the reincorporation, the Merger and the Merger Agreement are contained in our definitive proxy statement filed with the Securities and Exchange Commission on July 5, 2016, and within the Annual Report on Form 10-K of which these financial statements are a part in Item 1 thereof under the caption “Business - The Flamel Merger.”

Under Irish law, the Company can only pay dividends and repurchase shares out of distributable reserves, as discussed further in the Company's proxy statement filed with the SEC as of July 5, 2016. Upon completion of the Merger, the Company did not have any distributable reserves. On February 15, 2017, the Company filed a petition with the High Court of Ireland seeking the court's confirmation of a reduction of the Company's share premium so that it can be treated as distributable reserves for the purposes of Irish law. On March 6, 2017, the High Court issued its order approving the reduction of the Company's share premium which can be treated as distributable reserves.

Basis of Presentation. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). The consolidated financial statements include the accounts of the Company and all subsidiaries. All significant intercompany accounts and transactions have been eliminated.

Reclassifications and Immaterial Corrections of Prior Period Amounts. The consolidated financial statements for prior periods contain certain reclassifications to conform to the presentation used in 2016. Additionally, the Company has identified certain immaterial errors related to prior reporting periods. The Company has assessed the impact of the errors on its prior period financial statements and concluded that the errors were not material to those financial statements. Although the effect of the errors was not material to any previously issued financial statements, the cumulative effect of correcting the errors would have been material for the period ended December 31, 2016. Consequently, the Company has presented the effects of these errors and reclassifications on its prior period financial statements in the tables below. In future filings, the financial statements for comparative periods affected by these errors and reclassifications will be revised.

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Twelve Months Ended December 31, 2014
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(b)		(f)			As revised

Product sales and services	$	11,993		$	200	$	—		$	12,193
Total revenue	14,775			200		—			14,975
Operating income (loss)	(93,857		)	200		—			(93,657		)
Income (loss) before income taxes	(90,331		)	200		—			(90,131		)
Income tax provision (benefit)	(1,407		)	70		693			(644		)
Net income (loss) from continuing operations	(88,924		)	130		(693		)	(89,487		)
Net income (loss)	(84,906		)	130		(693		)	(85,469		)
Net loss per share - basic	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)
Net loss per share - diluted	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)



	Twelve Months Ended December 31, 2015
			Correction of Immaterial Errors
Consolidated Statement of Income:	As filed		(a)			(b)			(c)			As revised

Product sales and services	$	172,488	$	—		$	(200	)	$	—		$	172,288
Total revenue	173,209		—			(200		)	—			173,009
Cost of products and services sold	10,921		—			—			489			11,410
Total operating expenses	101,762		—			—			489			102,251
Operating income (loss)	71,447		—			(200		)	(489		)	70,758
Income (loss) before income taxes	78,394		—			(200		)	(489		)	77,705
Income tax provision (benefit)	37,735		(1,587		)	(70		)	(171		)	35,907
Net income (loss) from continuing operations	40,659		1,587			(130		)	(318		)	41,798
Net income (loss)	40,659		1,587			(130		)	(318		)	41,798
Net income (loss) per share - basic	$	1.00	$	0.04		$	—		$	(0.01	)	1.03
Net income (loss) per share - diluted	$	0.93	$	0.04		$	—		$	(0.01	)	$	0.96



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(c)			(d)			(e)			(g)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(228		)	(171		)	—			—			76		—
Total current liabilities	48,788			(228		)	(171		)	(3,410		)	193			76		45,248
Long-term related party payable	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,359		)	—			—			—			8		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)

Reflects the correction of a $200 overstatement of revenue in the first quarter of 2015 resulting from errors in certain estimates of ending inventory amounts at our wholesalers which were originally corrected in the first quarter of 2015 but should have been recorded in the fourth quarter of 2014. As this item was originally corrected in the first quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(c)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(d)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(e)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(f)

Reflects the correction of $2,606 of income tax benefits from stock-based compensation and certain other items which were originally recorded in the fourth quarter of 2015 but should have been recorded in prior periods ($360 in 2012, $333 in 2013, $(693) in 2014, and $830, $1,026 and $750 in the first, second and third quarters of 2015, respectively). As these items were originally corrected in the fourth quarter of 2015, no adjustment was required to correct the consolidated balance sheet at December 31, 2015.


(g)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (f) above.

In addition to the specific amounts identified within the tables above, the Company also changed the names of the previously-reported “Interest expense – changes in fair value of related party financing related contingent consideration” line on the consolidated statement of income (loss) to “Other expense – changes in fair value of related party payable”, and the previously-reported “Long-term related party contingent consideration payable” line on the consolidated balance sheet to “Long-term related party payable” to better reflect the underlying nature of certain royalty agreements.

While the balance sheet revisions and reclassifications noted in the tables above impact their corresponding captions within the cash flows provided by (used in) operating activities section of the Company’s consolidated statements of cash flows in each quarterly period of 2015, there was no impact to the total net cash provided by (used in) operating activities in any of these periods.

Additionally, $76,213 of marketable securities as of December 31, 2015 were reclassified from a Level 1 fair value hierarchy classification, as reported in prior filings, to a Level 2 classification based on the criteria set forth in Note 3: Fair Value Measurement.

Revenue

Revenue includes sales of pharmaceutical products, amortization of licensing fees and, if any, milestone payments for R&D achievements.

Product Sales and Services

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

For generic and branded products sold in mature markets where the ultimate net selling price to the customer is estimable, the Company recognizes revenues upon shipment to the wholesaler. For new product launches, we recognize revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns and other deductions may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. In connection with the third quarter 2016 launch of Akovaz, we determined that sufficient data was available to determine the ultimate net selling price to the customer, and therefore, we began to recognize revenue upon shipment to our wholesaler customers.

Prior to the second quarter 2016, we did not have sufficient historical data to estimate certain revenue deductions. As such, we could not accurately estimate the ultimate net selling price of our Avadel Legacy Pharmaceuticals (formerly Éclat) portfolio of products. As a result, we delayed revenue recognition on these products until the wholesaler sold the product through to its customers.

During the second quarter of 2016, it was determined that we now had sufficient evidence, history, data and internal controls to estimate the ultimate selling price of our products upon shipment from our warehouse to our customers, the wholesalers. Accordingly, we discontinued the sell-through revenue approach and now recognize revenue once the product is shipped from the warehouse to the wholesaler. As a result of this change in accounting estimate, we recognized $5,981 in additional revenue, or $0.05 per diluted share, for the twelve months ended December 31, 2016 that previously would have been deferred until sold by the wholesalers to the hospitals.

License and Research Revenue

Our license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over the projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured. For the year ended December 31, 2016, we recognized $3,024 of revenue from license agreements.

Government Grants

The Company receives financial support for various research or investment projects from governmental agencies.

From time to time we receive funds, primarily from the French government, to finance certain R&D projects. These funds are repayable on commercial success of the project. In the absence of commercial success, the Company is released of its obligation to repay the funds and as such the funds are recognized in the consolidated statements of income (loss) as an offset to R&D expense. The absence of commercial success must be formally confirmed by the granting authority. Should the Company wish to discontinue the R&D to which the funding is associated, the granting authority must be informed and a determination made as to how much, if any, of the grant must be repaid.

Research and Development

Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses, and other research and development expenses. Clinical studies and outside services costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third party fees. Personnel expenses relate primarily to salaries, benefits and stock-based compensation. Other research and development expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&D expenditures are charged to operations as incurred.

The Company recognizes R&D tax credits received from the French government for spending on innovative R&D as an offset of R&D expenses.

Stock-based Compensation

The Company accounts for stock-based compensation based on grant-date fair value estimated in accordance with ASC 718. The fair value of stock options and warrants is estimated using Black-Scholes option-pricing valuation models (“Black-Scholes model”). As required by the Black-Sholes model, estimates are made of the underlying volatility of AVDL stock, a risk-free rate and an expected term of the option or warrant. We estimated the expected term using a simplified method, as we do not have enough historical exercise data for a majority of such options and warrants upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.

Income Taxes

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.

We record uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheet.

Discontinued Operations

The Company followed the guidance in Financial Accounting Standards Board Accounting Standards Codification (ASC) Topic 205 Presentation of Financial Statements (ASC 205), Topic 360 Property, Plant and Equipment (ASC 360) and Accounting Standards Update (ASU 2014-8), Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity in determining the accounting for the divestiture of the Company's Pessac, France facility and the related business to Recipharm in December 2014. In 2014, the Company opted to early adopt the provisions of ASU 2014-8 as management believed that all criteria for presenting the disposal of Pessac facility and its business as a discontinued operation were met, and that presenting the disposal as a discontinued operation would better reflect the Company's ongoing operations.

The divestiture of the Pessac facility was part of a strategic shift that had and will have a major effect on the Company’s operations and financial results. Prior to the acquisition of the Avadel Legacy Pharmaceutical (formerly Éclat) products in March 2012, the Company’s primary focus was to develop and license its proprietary drug delivery platforms (Micropump®, LiquiTime®, Trigger Lock™ and Medusa™) with pharmaceutical companies and biotechnology partners (e.g. the licensing of Micropump® to GSK to develop Coreg CR® with GSK bringing and commercializing the product to market). With the acquisition of the Avadel Legacy Pharmaceutical (formerly Éclat) products, the Company shifted its focus to combining novel, high-value internally developed products with its leading drug delivery platforms -- reducing its reliance on products developed with partners -- and commercializing niche branded and generic pharmaceutical products. The divestiture of the Pessac facility to Recipharm and the transfer to Recipharm of the GSK’s Supply Agreement and royalty income relating to Coreg CR ® was an implementation of this strategic shift. Avadel sold over 50% of its historical revenues as a result of the divestiture of the Pessac facility, which has a major impact on the Company’s operations and results.

The divestiture of the Pessac facility was accomplished in a single transaction and the assets, contracts and liabilities referred to in the Asset Purchase Agreement signed between Avadel and Recipharm were determined to represent a disposal group. This disposal group was considered to be a component of the Company. While the Pessac facility and its related business were not identified as reportable segment or operating segment, as the Company operates in only one segment, the Pessac facility and its related business is considered to be an asset group as the transferred assets, liabilities and contracts represent the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. The Company transferred all future cash outflows and inflows relating to the Pessac Facility that can be clearly distinguished operationally and for financial reporting purposes.

The results of discontinued operations, less income taxes, have been reported as a separate component of income in the consolidated statements of income (loss). The assets and liabilities of the discontinued operation have been reported separately in the asset and liability sections of the consolidated balance sheets for the periods presented therein. Note 19: Discontinued Operations contains a description of the facts and circumstances related to the disposal, the gain and loss on disposal and the specific line items included in the consolidated statements of income (loss), consolidated balance sheets and consolidated statements of cash flows relative to the disposal group.

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.

Marketable Securities

The Company’s marketable securities are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive income (“AOCI”) in shareholders’ equity, with the exception of unrealized losses believed to be other-than-temporary, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.

Accounts Receivable

Accounts receivable are stated at amounts invoiced net of allowances for doubtful accounts and certain other gross to net deductions. The Company makes judgments as to its ability to collect outstanding receivables and provides allowances for the portion of receivables deemed uncollectible. Provision is made based upon a specific review of all significant outstanding invoices. A majority of accounts receivable is due from three significant customers. See Note 18: Company Operations by Product, Customer and Geographic Area.

Inventories

Inventories consist of raw materials and finished products, which are stated at lower of cost or market determined under the first-in, first-out ("FIFO") method. Raw materials used in the production of pre-clinical and clinical products are expensed as R&D costs when consumed. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis.

Property and Equipment

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:



Laboratory equipment	4-8 years
Office and computer equipment	3 years
Leasehold improvements, furniture, fixtures and fittings	5-10 years

Goodwill

Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and has a single reporting unit associated with the development and commercialization of pharmaceutical products. The annual test for goodwill impairment is a two-step process. The first step is a comparison of the fair value of the reporting unit with its carrying amount, including goodwill. If this step indicates impairment, then, in the second step, the loss is measured as the excess of recorded goodwill over the implied fair value of the goodwill. Implied fair value of goodwill is the excess of the fair value of the reporting unit as a whole over the fair value of all separately identified assets and liabilities within the reporting unit. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company uses projections of future discounted cash flows and takes into account assumptions regarding the evolution of the market and the Company's ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in potential associated impairment. During the fourth quarter of 2016, we performed our required annual impairment test of goodwill and have determined that no impairment of goodwill existed at December 31, 2016 or 2015.

Long-Lived Assets

Long-lived assets include fixed assets and intangible assets. Intangible assets consist primarily of purchased licenses, in-process R&D and intangible assets recognized as part of the Éclat and FSC acquisitions. Acquired IPR&D has an indefinite life and is not amortized until completion and development of the project, at which time the IPR&D becomes an amortizable asset. Amortization of acquired IPR&D is computed using the straight-line method over the estimated useful life of the assets.

Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. The Company has determined that no indications of impairment existed at December 31, 2016 or 2015.

Acquisition-related Contingent Consideration

The acquisition-related contingent consideration payables arising from the acquisition of Éclat Pharmaceuticals (i.e., our Avadel Legacy Pharmaceutical products business) and FSC are accounted for at fair-value (see Note 10: Long-Term Related Party Payable). The fair value of the warrants issued in connection with the Éclat acquisition are estimated using a Black-Scholes option pricing model. The fair value of acquisition-related contingent consideration payable is estimated using a discounted cash flow model based on the long-term sales or gross profit forecasts of the specified Éclat or FSC products using an appropriate discount rate. There are a number of estimates used when determining the fair value of these earn-out payments. These estimates include, but are not limited to, the long-term pricing environment, market size, market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows. These estimates can and often do change based on changes in current market conditions, competition, management judgment and other factors. Changes to these estimates can have and have had a material impact on our consolidated statements of income (loss), balance sheets and statements of cash flows. Changes in fair value of these liabilities are recorded in the consolidated statements of income (loss) within operating expenses as changes in fair value of related party contingent consideration.

Financing-related Royalty Agreements

We also entered into two royalty agreements with related parties in connection with certain financing arrangements. We elected the fair value option for the measurement of the financing-related contingent consideration payable associated with the royalty agreements with certain Deerfield and Broadfin entities, both of whom are related parties (see Note 10: Long-Term Related Party Payable). The fair value of financing-related royalty agreements is estimated using many of the components used to determine the fair value of the acquisition-related contingent consideration noted above. Changes to these components can also have a material impact on our consolidated statements of income (loss), balance sheets and statements of cash flows. Changes in the fair value of this liability are recorded in the consolidated statements of income (loss) as other expense - changes in fair value of related party payable.

Foreign Currency Translation

At December 31, 2016, the reporting currency of the Company and its wholly-owned subsidiaries is the U.S. dollar. Prior to December 31, 2016, each of the Company's non-U.S. subsidiaries and the parent entity, Flamel, used the Euro as their functional currency. At December 31, 2016, in conjunction with the Merger described above, Avadel determined the U.S. dollar is its functional currency. Subsidiaries and entities that do not use the U.S. dollar as their functional currency translate 1) profit and loss accounts at the average exchange rates during the reporting period, 2) assets and liabilities at period end exchange rates and 3) shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of shareholders' equity in accumulated other comprehensive loss. Assets and liabilities, excluding available-for-sale marketable securities, denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the consolidated statements of income (loss). Available-for-sale marketable securities denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the consolidated statements of comprehensive income (loss).

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including marketable securities and contingent liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the periods presented. Actual results could differ from those estimates under different assumptions or conditions.

Effect of New Accounting Standards	12 Months Ended
Effect of New Accounting Standards	Dec. 31, 2016
Accounting Changes and Error Corrections [Abstract]
Effect of New Accounting Standards	Effect of New Accounting Standards In January 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2017-04, "Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment." This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of fiscal 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations. In January, 2017, the FASB issued ASU 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business." This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. This guidance is effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted for transactions not previously reported in the Company's consolidated financial statements. The Company will assess the timing of adoption and impact of this guidance on further transactions. In October 2016, the FASB issued ASU 2016-16, "Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory," which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. ASU 2016-16 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company is currently in the process of evaluating the impact of ASU 2016-16 on its consolidated financial statements. In 2017, the Company plans to adopt the provisions of ASU 2016-16, related to Intra-Entity Transfers of Assets Other Than Inventory. Adoption of ASU 2016-16 will eliminate the $10,342 income tax deferred charge recorded within the consolidated balance sheet as of December 31, 2016. In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company does not believe this standard will materially impact its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU 2016-10 “Identifying Performance Obligations and Licensing,” and ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of its adoption on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” which amends Accounting Standards Codification (“ASC”) Topic 718 “Compensation – Stock Compensation”. This update simplifies several aspects of accounting for share-based payment awards to employees, including the accounting for income taxes, classification of awards as either equity or liabilities and classification in the statement of cash flows. The standard is effective for annual reporting periods beginning after December 15, 2016. The Company does not believe this standard will materially impact its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on its consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." The amendments in this update address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and requires a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. Early adoption is not permitted. The new guidance will require the change in fair value of equity investments with readily determinable fair values to be recognized through the income statements. We are currently evaluating the full impact of the standard; however, upon adoption, the change in the fair value of our available-for-sale equity investments will be recognized in our consolidated statement of income (loss) rather than our consolidated statement of comprehensive income (loss). In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory" which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The effective date for the standard is for fiscal years beginning after December 15, 2016. The new standard is to be applied prospectively and early adoption is permitted. The Company does not expect ASU 2015-11 to have a material impact on its consolidated financial statements.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6507316

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Direct Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=66092750

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22583-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Indirect Effects of a Change in Accounting Principle
-URI http://asc.fasb.org/extlink&oid=6515603

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22580-107794

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.10-01.(b)(6))
-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Accounting Change
-URI http://asc.fasb.org/extlink&oid=6503790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64853466&loc=d3e22499-107794

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Retrospective Application
-URI http://asc.fasb.org/extlink&oid=6523989

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e765-108305

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 270
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68064558&loc=d3e725-108305

+ Details

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

ASC 820, Fair Value Measurements and Disclosures defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:


•	Income approach, which is based on the present value of a future stream of net cash flows.


•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:


•	Level 1 - Quoted prices for identical assets or liabilities in active markets.


•	Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.


•	Level 3 - Unobservable inputs that reflect estimates and assumptions.

The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:



	As of December 31, 2016						As of December 31, 2015
Fair Value Measurements:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3

Marketable securities (see Note 4)
Equity securities	$	4,033	$	—	$	—	$	3,525	$	—	$	—
Time deposits	—		—		—		—		13,641		—
Corporate bonds	—		57,348		—		—		42,139		—
Government securities - U.S.	—		42,814		—		—		13,738		—
Government securities - Non-U.S.	—		233		—		—		1,063		—
Other fixed-income securities	—		10,471		—		—		3,992		—
Other securities	—		81		—		—		1,640		—
Total assets	$	4,033	$	110,947	$	—	$	3,525	$	76,213	$	—

Related party payable (see Note 10)	—		—		169,347		—		—		122,693
Total liabilities	$	—	$	—	$	169,347	$	—	$	—	$	122,693

A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the fiscal year ended December 31, 2016 and December 31, 2015, there were no transfers in and out of Level 1, 2, or 3. During the twelve months ended December 31, 2016, 2015 and 2014, we did not recognize any other-than-temporary impairment loss.

In 2016, as part of management's review of the consolidated financial statements, we reassessed the fair value level of certain investment grade marketable securities and as a result moved all corporate bonds, government securities, other fixed income securities, and certain other securities from Level 1 to Level 2 assets.

Some of the Company's financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. Additionally, the Company's long-term debt is reflected in the balance sheet at carrying value, which approximates fair value, as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

12 Months Ended

Dec. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Marketable Securities

The Company has investments in available-for-sale marketable securities which are recorded at fair market value. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects.

The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of December 31, 2016 and 2015, respectively:



	2016
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	3,689	$	409	$	(65	)	$	4,033
Corporate bonds	57,871		89		(612		)	57,348
Government securities - U.S.	43,049		515		(750		)	42,814
Government securities - Non-U.S.	247		—		(14		)	233
Other fixed-income securities	10,281		221		(31		)	10,471
Other securities	81		—		—			81
Total	$	115,218	$	1,234	$	(1,472	)	$	114,980



	2015
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	3,510	$	29	$	(14	)	$	3,525
Time deposits	13,641		—		—			13,641
Corporate bonds	42,129		1,520		(1,510		)	42,139
Government securities - U.S.	13,822		4		(88		)	13,738
Government securities - Non-U.S.	1,112		8		(57		)	1,063
Other fixed-income securities	4,008		—		(16		)	3,992
Other securities	1,663		—		(23		)	1,640
Total	$	79,885	$	1,561	$	(1,708	)	$	79,738

We determine realized gains or losses on the sale of marketable securities on a specific identification method. We recognized gross realized gains of $1,265, $241, and $24 for the twelve months ended December 31, 2016, 2015, and 2014, respectively. These realized gains were offset by realized losses of $586, $677, and $81 for the twelve-months ended December 31, 2016, 2015, and 2014, respectively. We reflect these gains and losses as a component of investment and other income in the accompanying consolidated statements of income (loss).

The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of December 31, 2016:



	Maturities
Marketable Securities:	Less than 1 Year		1-5 Years		5-10 Years		Greater than 10 Years		Total

Equity securities	$	4,033	$	—	$	—	$	—	$	4,033
Corporate bonds	11,933		39,325		5,655		435		57,348
Government securities - U.S.	2,258		33,270		1,530		5,756		42,814
Government securities - Non-U.S.	—		—		233		—		233
Other fixed-income securities	—		8,199		1,996		276		10,471
Other securities	81		—		—		—		81
Total	$	18,305	$	80,794	$	9,414	$	6,467	$	114,980

The Company has classified our investment in available-for-sale marketable securities as current assets in the consolidated balance sheets at December 31, 2016 and 2015, respectively, as the securities need to be available for use, if required, to fund current operations. There are no restrictions placed around the sale of any securities in our investment portfolio.

Inventory

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Inventory

The principal categories of inventories, net reserves of $3,223 and $806 in 2016 and 2015, respectively, are comprised of the following as of December 31:



Inventory:	2016		2015

Finished goods	$	2,429	$	2,545
Raw materials	829		1,121
Total	$	3,258	$	3,666

Property and Equipment, net

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Property and Equipment, net

The principal categories of property and equipment, net at December 31, 2016 and 2015, respectively, are as follows:



Property and Equipment, net:	2016			2015

Laboratory equipment	$	9,019		$	9,963
Office and computer equipment	2,519			2,968
Furniture, fixtures and fittings	4,239			4,315
Less - accumulated depreciation	(12,457		)	(14,630		)
Total	$	3,320		$	2,616

Depreciation expense for the years ended December 31, 2016, 2015 and 2014 was $601, $568 and $681, respectively.

Acquisitions

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Acquisitions

On February 5, 2016, the Company completed its acquisition of FSC, previously a Charlotte, North Carolina-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients, from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a related party.

This acquisition has been accounted for using the acquisition method of accounting and, accordingly, its results are included in the Company's consolidated financial statements from the date of acquisition. Total consideration to acquire FSC is estimated to be $21,659, and was funded with a combination of the following, partially offset by $467 as a result of a net working capital settlement from the seller:


•	$15,000 long-term liability to Deerfield. Under the terms of the acquisition agreement, the Company will pay $1,050 annually for five years with a final payment in January 2021 of $15,000.


•	an estimate of $6,659 in contingent consideration to Deerfield. Under the terms of the acquisition agreement, the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

These items are reported in related party payable within the Company’s consolidated balance sheet, and is further disclosed in Note 10: Long-Term Related Party Payable.

The Company finalized its purchase price allocation as noted in the following table. The fair values assigned to the acquired assets and liabilities have been recognized as follows:



	2016
Assigned Fair Value:	Final

Accounts receivable	$	142
Inventories	1,135
Prepaid expenses and other current assets	1,712
Intangible assets:
Acquired product marketing rights	16,600
Acquired developed technology	4,300
Deferred tax assets	853
Other assets	277
Accounts payable and other liabilities	(3,827		)
Total	$	21,192

A portion of the transaction attributable to certain intangible assets was taxable for income tax purposes resulting in recording some of the assets at fair value for both book and tax purposes. Transaction expenses were not material. The useful lives on FSC acquired intangible assets range from nine to fifteen years.

After its acquisition on February 5, 2016, FSC contributed $5,985 to the Company's net sales for the twelve-month period ended December 31, 2016. FSC incurred a loss of $5,839 for the twelve-month period ended December 31, 2016.

Had the FSC acquisition been completed as of the beginning of 2015, the Company's unaudited pro forma net sales and net loss for the twelve months ended December 31, 2016 and 2015 would have been as follows:



Pro Forma Net Revenue and Income (Losses):	2016			2015

Net revenues	$	150,721		$	178,104
Net income (loss)	(42,290		)	30,965

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Goodwill and Intangible Assets

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

The Company's amortizable and unamortizable intangible assets at December 31, 2016 and 2015, respectively, are as follows:



	2016							2015
Goodwill and Intangible Assets:	Gross Value		Accumulated Amortization			Net Book Value		Gross Value		Accumulated Amortization			Net Book Value

Amortizable intangible assets:
Acquired IPR&D - Bloxiverz	$	35,248	$	(35,248	)	$	—	$	35,248	$	(23,498	)	$	11,750
Acquired IPR&D - Vazculep	12,061		(8,801		)	3,260		12,061		(7,986		)	4,075
Acquired product marketing rights	16,600		(1,019		)	15,581		—		—			—
Acquired developed technology	4,300		(304		)	3,996		—		—			—
Total amortizable intangible assets	$	68,209	$	(45,372	)	$	22,837	$	47,309	$	(31,484	)	$	15,825

Unamortizable intangible assets:
Goodwill	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491
Total unamortizable intangible assets	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $13,888, $12,564 and $11,749 for the years ended December 31, 2016, 2015 and 2014, respectively.

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to fifteen years, using the straight-line method. Total future amortization of intangible assets for the next five years is as follows:



Estimated Amortization Expense:	Balance

2017	$	2,258
2018	2,258
2019	2,258
2020	2,258
2021	1,443

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt French government agencies provide financing to French companies for research and development. At December 31, 2016 and 2015, the Company had outstanding loans of $815 and $1,118, respectively for various programs. These loans do not bear interest and are repayable only in the event the research project is technically or commercially successful. Potential repayment is scheduled to occur through 2019. During the years ended December 31, 2016, 2015 and 2014, the Company repaid $277, $747 and $355, of loans associated with specific research projects, respectively. In addition, during 2015 the Company received waivers of repayment for the remaining portion of certain loans of $1,498 on the basis of limited commercial and technical success. Amounts waived are reported as reductions to R&D expenses in the Company’s consolidated statements of income (loss). No such waivers were received during 2016 or 2014.

Long-Term Related Party Payable

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Long-Term Related Party Payable

Long-term related party payable and related activity are reported at fair value and consist of the following at December 31, 2016 and 2015, respectively:



				Activity during the Twelve Months Ended December 31, 2016
									Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, December 31, 2016

Acquisition-related:
Warrants - Éclat Pharmaceuticals ^(a)	$	20,617		$	—	$	—		$	(9,400	)	$	—	$	11,217
Earn-out payments - Éclat Pharmaceuticals ^(b)	90,468			—		(26,700		)	57,609			—		121,377
Royalty agreement - FSC ^(c)	—			6,659		(444		)	1,076			—		7,291
Financing-related:														—
Royalty agreement - Deerfield ^(d)	7,862			—		(2,501		)	—			4,433		9,794
Royalty agreement - Broadfin ^(e)	3,746			—		(1,193		)	—			2,115		4,668
Long-term liability - FSC ^(f)	—			15,000		—			—			—		15,000
Total related party payable	122,693			$	21,659	$	(30,838	)	$	49,285		$	6,548	169,347
Less: current portion	(25,204		)											(34,177		)
Total long-term related party payable	$	97,489												$	135,170

Each of the above items is associated with related parties as further described in Note 20: Related Party Transactions.

(a)

As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Avadel. One warrant is exercisable for 2,200 ordinary shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 ordinary shares at an exercise price of $11.00 per share.

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of December 31, 2016 and 2015:



Warrant Assumptions:	2016			2015

Weighted average exercise price per share	$	8.63		$	8.63
Expected term (years)	1.25			2.25
Expected volatility	54.20		%	64.54		%
Risk-free interest rate	0.94		%	0.93		%
Expected dividend yield	—			—

These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date.

Expected term: The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life.

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price for a period approximating the expected term.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The Company has not distributed any dividends since its inception and has no plan to distribute dividends in the foreseeable future.

At the closing date of the 2012 Éclat acquisition and at December 31, 2016, it was uncertain as to whether the Company would ultimately fulfill its obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a long-term liability. This classification as a long-term liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro.

(b)

In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.


(c)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.


(d)	As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.


(e)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.


(f)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000. Substantially all of FSC's, and its subsidiaries, assets are pledged as collateral under this agreement.

At December 31, 2016, the fair value of each related party payable listed in (b) through (e) above was estimated using a discounted cash flow model based on probability-adjusted annual net revenues or gross profit, as appropriate, of each of the specified Éclat and FSC products using an appropriate risk-adjusted discount rate ranging from 15% to 22%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the Consolidated Statements of Income (Loss) in the line items entitled "Changes in fair value of related party contingent consideration" for items noted in (b) and (c) above and in "Other expense - changes in fair value of related party payable" for items (d) and (e) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements for more information on key assumptions used to determine the fair value of these liabilities.

The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (d) and (e) above. These financing-related liabilities are recorded at fair market value on the consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the consolidated statements of income (loss).

The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the twelve-month periods ended December 31, 2016, 2015 and 2014:



Related Party Payable:	Balance

Balance at December 31, 2013	65,670
Payment of related party payable	(11,936	)
Fair value adjustments ⁽¹⁾	61,016
Balance at December 31, 2014	114,750
Payment of related party payable	(27,897	)
Fair value adjustments ⁽¹⁾	35,840
Balance at December 31, 2015	122,693
Additions ⁽²⁾	21,659
Payment of related party payable	(30,838	)
Fair value adjustments ⁽¹⁾	55,833
Balance at December 31, 2016	169,347

⁽¹⁾Fair value adjustments are reported as Changes in fair value of related party contingent consideration and Other expense - changes in fair value of related party payable in the Consolidated Statements of Income (Loss).

⁽²⁾Relates to the acquisition of FSC. See items (c) and (f) above.

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

The components of income (loss) before income taxes for the years ended December 31, are as follows:



Income (Loss) Before Income Taxes:	2016			2015			2014

Ireland	$	(22,866	)	$	(29,469	)	$	—
United States	32,786			100,552			(89,739		)
France	(19,638		)	6,622			(392		)
Total income (loss) before income taxes	$	(9,718	)	$	77,705		$	(90,131	)

The income tax provision (benefit) for the years ended December 31, is as follows:



Income Tax Provision (Benefit):	2016			2015			2014

Current:
United States - Federal	$	30,738		$	33,289		$	—
United States - State	1,081			970			—
France	5,267			1,657			1,400
Total current	37,086			35,916			1,400

Deferred:
United States - Federal	(6,443		)	504			(1,713		)
United States - State	(23		)	1,234			(331		)
France	938			(1,747		)	—
Total deferred	(5,528		)	(9		)	(2,044		)

Income tax provision (benefit)	$	31,558		$	35,907		$	(644	)

The items accounting for the difference between the income tax provision (benefit) computed at the jurisdiction of incorporation statutory rate and the Company's effective tax rate are as follows for the years ended December 31:



Reconciliation to Effective Income Tax Rate:	2016			2015			2014

Statutory tax rate ⁽¹⁾	12.5		%	33.3		%	33.3		%
Non-deductible changes in fair value of contingent consideration	(165.0		)%	11.9		%	(24.8		)%
Change in valuation allowance	11.8		%	(9.6		)%	5.3		%
Income tax deferred charge	(9.7		)%	1.3		%	(16.9		)%
International tax rates differential	(31.9		)%	11.0		%	6.7		%
Nondeductible stock based compensation	(14.8		)%	1.3		%	(0.8		)%
Cross-border merger	(100.6		)%	—		%	—		%
Unrecognized tax benefit	(15.2		)%	0.4		%	—		%
State and local taxes (net of federal)	(9.6		)%	1.5		%	0.3		%
Other	(2.3		)%	(4.9		)%	(2.3		)%
Effective income tax rate	(324.8		)%	46.2		%	0.8		%

Income tax provision (benefit) - at statutory tax rate	$	(1,215	)	$	25,876		$	(30,013	)
Non-deductible changes in fair value of contingent consideration	16,036			9,249			22,326
Change in valuation allowance	(1,143		)	(7,425		)	(4,732		)
Income tax deferred charge	938			980			15,273
International tax rates differential	3,097			8,547			(6,023		)
Nondeductible stock based compensation	1,436			1,004			693
Cross-border merger	9,773			—			—
Unrecognized tax benefit	1,475			290			—
State and local taxes (net of federal)	934			1,170			(228		)
Other	227			(3,784		)	2,060
Income tax provision (benefit) - at effective income tax rate	$	31,558		$	35,907		$	(644	)

⁽¹⁾ The statutory rate reflects the Irish statutory tax rate of 12.5% for fiscal 2016, and the French statutory tax rate of 33.3% for fiscal 2015 and 2014.

In 2016, the income tax provision decreased by $4,349 when compared to the same period in 2015. The primary reason for the decrease in the income tax provision is a substantially lower level of pre-tax book income in the United States and France. Increases in the amount of nondeductible expenses due to changes in the fair value of contingent consideration and a reduced amount of income tax benefit from the release of valuation allowances partially offset the income tax benefit from the reduced amount of pre-tax book income in 2016, when compared to 2015. The Company also recorded $9,773 of income tax provision in 2016 related to the cross-border merger.

In 2015, the income tax provision increased by $36,551 when compared to the same period in 2014. The primary reason for the large increase in the income tax provision was a substantial increase in the level of pre-tax book income in the United States and France. Decreases in the amount of nondeductible expenses due to changes in the fair value of contingent consideration and an increase in the benefit from the release of valuation allowances partially offset the income tax provision from the increased amount of pre-tax book income in 2015, when compared to 2014. In 2014, the Company recorded $15,273 of income tax provision related to the transfer of intellectual property from France to Ireland, which did not reoccur in 2015.

Unrecognized Tax Benefits

The Company or one of its subsidiaries files income tax returns in Ireland, France, United States and various states. With few exceptions, the Company is no longer subject to Irish, French, US Federal, and state and local examinations for years before 2012. The Internal Revenue Service (IRS) commenced an examination of the Company's US income tax return for 2015 in the 4th quarter of 2016 that is anticipated to be completed by the end of 2017.

The following table summarizes the activity related to the Company's unrecognized tax benefits for the twelve months ended December 31:



Unrecognized Tax Benefit Activity	2016			2015		2014

Balance at January 1:	$	448		$	—	$	—
Additions based on tax positions related to the current year	1,578			448		—
Additions (reductions) for tax positions of prior years	(340		)	—		—
Statute of limitations expiration	—			—		—
Settlements	—			—		—
Balance at December 31:	$	1,686		$	448	$	—

It is reasonably possible that within the next twelve months, as a result of activities performed in various jurisdictions, that the unrecognized tax benefits could change by up to $250. Interest and penalties could change by up to $50.

At December 31, 2016, 2015, and 2014, there are $1,565, $291, and $0 of unrecognized tax benefits that if recognized would affect the annual effective tax rate.

The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax expense. During the years ended December 31, 2016, 2015, and 2014, the Company recognized approximately $26, $0, and $0 in interest and penalties. The Company had approximately $27, and $0 for the payment of interest and penalties accrued at December 31, 2016, and 2015 respectively.

Deferred Tax Assets (Liabilities)

Deferred income tax provisions reflect the effect of temporary differences between consolidated financial statement and tax reporting of income and expense items. The net deferred tax assets/liabilities at December 31, 2016 and 2015 resulted from the following temporary differences:



Net Deferred Tax Assets and Liabilities:	2016			2015

Deferred tax assets:
Net operating loss carryforwards	$	11,566		$	44,587
Stock based compensation	5,012			1,767
Fair value royalty agreements	3,386			2,435
Fair value contingent consideration	2,152			1,348
Other	583			1,037
Total deferred tax assets	22,699			51,174
Valuation allowances	(7,599		)	(45,516		)
Net deferred tax assets	15,100			5,658

Deferred tax liabilities:
Amortization	(4,349		)	(5,649		)
Accounts receivable	(3,319		)	—
Total deferred tax liabilities	(7,668		)	(5,649		)

Net deferred tax assets	$	7,432		$	9

At December 31, 2016, the Company had $45,907 of net operating losses in Ireland that do not have an expiration date and $14,920 of net operating losses in the United States that expire 2033 through 2035. The US net operating losses were acquired as part of the acquisition of FSC. A valuation allowance is recorded if, based on the weight of available evidence, it is more likely than not that a deferred tax asset will not be realized. This assessment is based on an evaluation of the level of historical taxable income and projections for future taxable income. For the year ended December 31, 2016, the Company recorded $5,738 of valuation allowances related to Irish net operating losses and $1,272 of valuation allowance on U.S. net operating losses. The U.S. net operating losses are subject to an annual limitation as a result of the acquisition of FSC under internal revenue code section 382 and will not be fully utilized before they expire. In 2016, the Company removed all French net operating losses and the corresponding valuation allowances from the inventory of deferred tax assets as a result of the cross-border merger. For the year ended December 31, 2015, the Company recorded $40,959 and $3,628 of valuation allowances related to French and Irish net operating losses, respectively. The Company believes that it will generate sufficient future taxable income to realize the tax benefits related to the remaining net deferred tax assets.

We recorded a valuation allowance against all of our net operating losses in Ireland as of both December 31, 2016, and December 31, 2015. We intend to continue maintaining a full valuation allowance on the Irish net operating losses until there is sufficient evidence to support the reversal of all or some portion of these allowances. However, given our anticipated future earnings, we believe that there is a reasonable possibility that within the next 12 months, sufficient positive evidence may become available to allow us to reach a conclusion that a significant portion of the valuation allowance on the Irish net operating losses will no longer be needed. Release of the valuation allowance would result in the recognition of deferred tax assets and a decrease to income tax expense for the period the release is recorded. However, the exact timing and amount of the valuation allowance release are subject to change on the basis of the level of profitability that we are able to actually achieve.

At December 31, 2016, the Company has no unremitted earnings outside of Ireland as measured on a US GAAP basis. Whereas the measure of earnings for purposes of taxation of a distribution may differ for tax purposes, these earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends or if the Company were to sell its stock in the subsidiaries. It is not practicable to estimate the amount of deferred tax liability on such earnings, if any.

Research and Development Tax Credits Receivable

The French government provides tax credits to companies for spending on innovative R&D. These credits are recorded as an offset of R&D expenses and are credited against income taxes payable in each of the four years after being incurred or, if not so utilized, are recoverable in cash. As of December 31, 2016, the Company’s net Research tax credit receivable amounts to $1,775 and represents a gross research tax credit of $3,376, partially offset by current income tax payable of $1,601. The Company utilized $4,001 of research tax credits in 2016 to offset the tax cost of the cross-border merger. As of December 31, 2015, the Company’s net Research tax credit receivable amounts to $2,382 and represents a gross research tax credit of $3,720, partially offset by current income tax payable of $1,338.

Income Tax Deferred Charge

On December 16, 2014, the Company transferred all of its intangible intellectual property from its French entity to its Irish entity as a part of a global reorganization. The intellectual property includes patents on drug delivery platforms, clinical data sets and other intangible assets related to the pipeline of proprietary products in development. This intra-entity transaction resulted in a charge of $14,088 of related taxes to the French government in December 2014. As this represents an intra-entity transaction, no deferred tax asset has been recognized, but rather was originally recorded as $986 of prepaid expenses and $13,102 of a long-term Income tax deferred charge asset in accordance with ASC 740-10-25-3 (e). This income tax deferred charge asset is amortized over the tax life of the asset at a rate of 7% per year and will result in tax relief in Ireland of $8,500 from 2016 to 2029, subject to the ability to realize tax benefits for additional deductions. At December 31, 2016, the balance of these respective accounts was classified as prepaid expenses of $814 and Income tax deferred charge asset of $10,342. At December 31, 2015, the balance of these respective accounts was classified as prepaid expenses of $842 and Income tax deferred charge asset of $11,581. In 2017, the Company plans to adopt the provisions of ASU 2016-16, related to Intra-Entity Transfers of Assets Other Than Inventory. Adoption of ASU 2016-16 will eliminate the $11,156 income tax deferred charge recorded within the consolidated balance sheet as of December 31, 2016.

Cross-Border Merger

In 2016, we changed our jurisdiction of incorporation from France to Ireland by merging with and into our wholly owned Irish subsidiary. Information about the reincorporation was included in the definitive proxy statement filed with the Securities and Exchange Commission on July 5, 2016. Prior to the Merger, the Company submitted a request to the French tax authority seeking to benefit from a special regime for mergers and demergers, conditional upon a formal consent of the French tax authority which would allow for the deferral of a portion of the tax cost of the cross-border merger. However, to date the Company has not received, nor does it expect to receive consent resulting in the taxation of deferred profits and built in gains of the Company upon completion of the cross-border merger. The completion of the cross-border merger resulted in the recognition of a net income tax provision of $4,001, after considering tax benefits from the utilization of current and prior year French net operating losses. The Company was able to utilize $4,001 of French research and development tax credits to offset the remaining cost of the transaction. The Company also removed $111,495 of French net operating losses as the carryforward of the losses was contingent on receiving favorable consent from the French tax authority. The French net operating losses had a full valuation allowance resulting in no impact to the income tax provision.

On March 8, 2017, the European Court of Justice issued a ruling on case C-14/16, related to the treatment of cross-border mergers amongst entities that operate within Member States of the EU. Based on our initial assessment of the ruling, the Company may not have been required to apply for an advanced ruling from the French Tax Authority in order to defer a portion of the tax cost of the cross-border merger. The impact of this ruling could potentially generate an income tax benefit in 2017 of $3,848 by restoring $2,582 of French research and development tax credits and releasing $1,266 of unrecognized tax benefits originally recognized as part of the cross-border merger. The Company is in the process of assessing the administrative and legal options to potentially secure recovery of these benefits.

Post-Retirement Benefit Plans

12 Months Ended

Dec. 31, 2016

Compensation and Retirement Disclosure [Abstract]

Post-Retirement Benefits Plans

Post-Retirement Benefit Plans

Post-Retirement Benefit Contributions to French Government Agencies

The Company is required by French law to deduct specific monthly payroll amounts to support post-retirement benefit programs sponsored by the relevant government agencies in France. As the ultimate obligation is maintained by the French government agencies, there is no additional liability recorded by the Company in connection with these plans. Expenses recognized for these plans were $348 in 2016, $573 in 2015, and $719 in 2014.

Retirement Indemnity Obligation – France

French law requires the Company to provide for the payment of a lump sum retirement indemnity to French employees based upon years of service and compensation at retirement. The retirement indemnity has been actuarially calculated on the assumption of voluntary retirement at a government-defined retirement age. Benefits do not vest prior to retirement. Any actuarial gains or losses are recognized in the Company’s consolidated statements of income (loss) in the periods in which they occur.

The benefit obligation is calculated as the present value of estimated future benefits to be paid, using the following assumptions for the years ended December 31:



Retirement Benefit Obligation Assumptions:	2016		2015		2014

Compensation rate increase	3.00	%	3.00	%	3.00	%
Discount rate	1.31	%	2.03	%	1.49	%
Employee turn-over	Actuarial standard and average of the last 5 years
Average age of retirement	60 to 65 years actuarial standard based on age and professional status

Certain actuarial assumptions, such as discount rate, have a significant effect on the amounts reported for net periodic benefit cost and accrued retirement indemnity benefit obligation amounts. The discount rate is determined annually by benchmarking a published long-term bond index using the iBoxx € Corporates AA 10+ index.

Changes in the funded status of the retirement indemnity benefit plans were as follows for the years ended December 31:



Retirement Benefit Obligation Activity:	2016			2015

Retirement indemnity benefit obligation, beginning of year	$	2,170		$	2,350
Service cost	123			117
Interest cost	29			20
Benefits paid	—			(46		)
Actuarial loss (gain)	203			(27		)
Exchange rate changes	(94		)	(244		)
Retirement indemnity benefit obligation, end of year	$	2,431		$	2,170

The lump sum retirement indemnity is accrued on the Company’s consolidated balance sheets within non-current other liabilities, excluding the current portion. As these are not funded benefit plans, there are no respective assets recorded.

The future expected benefits to be paid over the next five years and for the five years thereafter is as follows for the years ended December 31:



Future Retirement Indemnity Benefit Obligation:	Balance

2017	$	—
2018	—
2019	11
2020	—
2021	—
Next five years	1,061
Total	1,072

Other Assets and Liabilities

12 Months Ended

Dec. 31, 2016

Other Liabilities Disclosure [Abstract]

Other Assets and Liabilities

Various other assets and liabilities are summarized as follows for the years ending December 31, is as follows:



Prepaid Expenses and Other Current Assets:	2016		2015

Valued-added tax recoverable	$	736	$	1,099
Prepaid expenses	3,442		2,921
Advance to suppliers and other current assets	1,265		518
Income tax receivable	451		3,526
Total	$	5,894	$	8,064



Other Non-Current Assets:	2016		2015

Deferred tax assets	$	7,432	$	9
Other	99		158
Total	$	7,531	$	167



Accrued Expenses	2016		2015

Accrued compensation	$	3,291	$	1,888
Accrued social charges	794		1,710
Customer allowances	7,981		5,710
Accrued contract research organization	1,764		—
Other	3,392		—
Total	$	17,222	$	9,308



Other Non-Current Liabilities	2016		2015

Provision for retirement indemnity	$	2,431	$	2,170
Customer allowances	905		—
Unrecognized tax benefits	1,565		291
Other	374		65
Total	$	5,275	$	2,526

Contingent Liabilities and Commitments

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Contingent Liabilities and Commitments

Litigation

The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At December 31, 2016 and 2015, there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s consolidated balance sheet, results of operations, cash flows or liquidity.

Material Commitments

The Company has commitments to purchase services from Recipharm Pessac for a total of $22,500 for a five-year period commencing January 1, 2015 (disclosed in Note 19: Discontinued Operations).

The Company has a commitment to purchase finished product from a contract manufacturer for a total of $7,238 during the one-year period commencing January 1, 2017.

The Company has a commitment to purchase finished product from a contract manufacturer for a twenty-year period commencing August 1, 2015 and ending July 31, 2035. The commitment for any individual year is contractually waived if the Company's net customer sales for that product exceed certain amounts in that same year. Maximum commitments for this arrangement, at 2016 pricing levels and excluding any waived commitments, are as follows for the years ended December 31:



Purchase Commitment:	Balance

2017	$	778
2018	1,032
2019	1,126
2020	1,126
2021	1,126
Thereafter	15,295
Total	$	20,483

The Company and its subsidiaries lease office facilities under noncancelable operating leases expiring at various dates. Rent expense, net of rental income, was $970, $752 and $844 in 2016, 2015, and 2014, respectively. Minimum rental commitments for non-cancelable leases in effect at December 31, 2016 are as follows:



Lease Commitment:	Balance

2017	$	1,117
2018	783
2019	717
2020	699
2021	441
Thereafter	600
Total	$	4,357

Other than the above commitments, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt, long-term related party payable, and post-retirement benefit plan obligations which are disclosed in Note 9: Long-Term Debt, Note 10: Long-Term Related Party Payable, and Note 12: Post-Retirement Benefit Plans, respectively.

The following table presents contractual obligations of the Company at December 31, 2016:



	Payments Due by Period
Contractual Obligations:	Total		Less than 1 Year		1 to 3 Years		3 to 5 Years		More than 5 Years

Long-term debt	$	815	$	268	$	547	$	—	$	—
Long-term related party payable (undiscounted)	278,236		35,226		57,466		60,587		124,957
Purchase commitments	41,721		12,266		11,908		2,252		15,295
Operating leases	4,982		1,390		1,837		1,155		600
Total contractual cash obligations	$	325,754	$	49,150	$	71,758	$	63,994	$	140,852

Equity Instruments and Stock Based Compensation

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity Instruments and Stock Based Compensation

Compensation expense included in the Company’s consolidated statements of income (loss) for all stock-based compensation arrangements was as follows for the periods ended December 31:



Stock-based Compensation Expense:	2016		2015		2014

Cost of products and services sold	$	—	$	—	$	38
Research and development	3,523		1,587		1,027
Selling, general and administrative	11,156		6,154		1,829
Total stock-based compensation expense	$	14,679	$	7,741	$	2,894

As of December 31, 2016, the Company expects $12,874 of unrecognized expense related to granted, but non-vested stock-based compensation arrangements to be incurred in future periods. This expense is expected to be recognized over a weighted average period of 3.2 years.

The excess tax benefit related to stock-based compensation recorded by the Company was $65 and $1,767, for the years ended December 31, 2016 and 2015. There was no similar amount for the year ended December 31, 2014.

Upon exercise of stock options or warrants, or upon the issuance of free share awards, the Company issues new shares.

Capital Stock

We have 500,000 shares of authorized ordinary shares with a nominal value of $0.01 per common share. As of December 31, 2016, we had 41,371 shares of ordinary shares issued and outstanding. The Board of Directors is authorized to issue preferred stock in series, and with respect to each series, to fix its designation, relative rights (including voting, dividend, conversion, sinking fund, and redemption rights), preferences (including dividends and liquidation) and limitations. We have 50,000 shares of authorized preferred stock, $0.01 nominal value, none of which is currently outstanding.

Determining the Fair Value of Stock Options and Warrants

The Company measures the total fair value of stock options and warrants on the grant date using the Black-Scholes option-pricing model and recognizes each grant's fair value as compensation expense over the period that the option or warrant vests. Options are granted to employees of the Company and generally become exercisable within four years following the grant date and expire ten years after the grant date. Warrants are typically issued to the Company’s Board of Directors as compensation for services rendered and generally become exercisable within one year following the grant date, and expire four years after the grant date.

The weighted-average assumptions under the Black-Scholes option-pricing model for stock option and warrant grants as of December 31, 2016, 2015 and 2014, are as follows:



Stock Option and Warrant Assumptions:	2016		2015		2014

Stock option grants:
Expected term (years)	6.25		6.25		6.25
Expected volatility	58.39	%	58.59	%	59.00	%
Risk-free interest rate	2.04	%	1.89	%	1.79	%
Expected dividend yield	—		—		—

Warrant grants:
Expected term (years)	2.50		2.50		2.50
Expected volatility	60.57	%	55.00	%	58.00	%
Risk-free interest rate	0.82	%	0.89	%	0.75	%
Expected dividend yield	—		—		—

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price for a period approximating the expected term.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The expected dividend yield is based on the Company's authorized periodic dividend and the Company's expectation for dividend yields over the expected term. The Company has not distributed any dividends since its inception, and has no plan to distribute dividends in the foreseeable future.

Stock Options

A summary of the combined stock option activity and other data for the Company's stock option plans for the year ended December 31, 2016 is as follows:



Stock Option Activity and Other Data:	Number of Stock Options		Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

Stock options outstanding, January 1, 2016	2,326		$	13.84
Granted	1,505		10.68
Exercised	(15	)	6.50
Forfeited	(6	)	14.35
Expired	(78	)	31.70
Stock options outstanding, December 31, 2016	3,732		$	12.07	8.48 years	$	3,681
Stock options exercisable, December 31, 2016	1,161		$	10.49	6.76 years	$	3,035

The aggregate intrinsic value of options exercised during the years ended December 31, 2016, 2015 and 2014 was $58, $10,063, and $3,789, respectively.

The weighted average grant date fair value of options granted during the years ended December 31, 2016, 2015 and 2014 was $6.14, $9.38 and $9.19 per share, respectively.

At December 31, 2016, there were 94 shares authorized for stock option grants in subsequent periods.

Warrants

A summary of the combined warrant activity and other data for the year ended December 31, 2016 is as follows:



Warrant Activity and Other Data:	Number of Warrants	Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

Warrants outstanding, January 1, 2016	668	$	16.97
Granted	291	13.59
Exercised	—	—
Forfeited	—	—
Expired	—	—
Warrants outstanding, December 31, 2016	959	$	16.05	2.47 years	$	276
Warrants exercisable, December 31, 2016	668	$	17.12	1.97 years	$	276

Each of the above warrants is convertible into one ordinary share. The aggregate intrinsic value of warrants exercised during the years ended December 31, 2016, 2015 and 2014 was $0, $2,698 and $3,107, respectively.

The weighted average grant date fair value of warrants granted during the years ended December 31, 2016, 2015 and 2014 was $2.99, $5.92 and $3.90 per share, respectively.

At December 31, 2016, an additional 3,300 warrants were outstanding and exercisable relative to consideration paid for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012. These warrants are not considered stock-based compensation and are therefore excluded from the above tables, and instead are addressed within Note 10: Long-Term Related Party Payable.

At December 31, 2016, there were 59 shares authorized for warrant grants in subsequent periods.

Free Share Awards

Free share awards represent Company shares issued free of charge to employees of the Company as compensation for services rendered. The Company measures the total fair value of free share awards on the grant date using the Company's stock price at the time of the grant. Free share awards granted prior to 2016 generally cliff vest at the end of a four-year vesting period, and are expensed over a two or four-year service period. Free share awards granted during 2016 were fully expensed at the date of grant as they contain no service requirement. Employees, however, are not free to trade these awards until the end of a two-year holding period.

A summary of the Company's free share awards as of December 31, 2016, and changes during the year then ended, is reflected in the table below.



Free Share Activity and Other Data:	Number of Free Share Awards		Weighted Average Grant Date Fair Value

Non-vested free share awards outstanding, January 1, 2016	226		$	13.95
Granted	463		12.11
Vested	(115	)	13.44
Forfeited	(1	)	16.27
Non-vested free shares awards outstanding, December 31, 2016	573		$	12.57

The weighted average grant date fair value of free share awards granted during the years ended December 31, 2016 and 2014 was $12.11 and $16.30, respectively. There were no free share awards granted in 2015.

At December 31, 2016, there were 290 shares authorized for free share award grants in subsequent periods.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Earnings (Loss) Per Share

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated using the weighted average number of shares outstanding during each period. The diluted earnings (loss) per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants.

A reconciliation of basic and diluted earnings (loss) per share, together with the related shares outstanding in thousands for the years ended December 31, is as follows:



Basic and Diluted Earnings (Loss) Per Share:	2016			2015		2014

Net income (loss)
Net income (loss) from continuing operations	$	(41,276	)	$	41,798	$	(89,487	)
Net income (loss) from discontinued operations	—			—		4,018
Net income (loss)	$	(41,276	)	$	41,798	$	(85,469	)

Weighted average shares:
Basic shares	41,248			40,580		36,214
Effect of dilutive securities—options and warrants outstanding	—			3,039		—
Diluted shares	41,248			43,619		36,214

Earnings (loss) per share - basic:
Continuing operations	$	(1.00	)	$	1.03	$	(2.47	)
Discontinued operations	—			—		0.11
Net income (loss) per share - basic	$	(1.00	)	$	1.03	$	(2.36	)

Earnings (loss) per share - diluted:
Continuing operations	$	(1.00	)	$	0.96	$	(2.47	)
Discontinued operations	—			—		0.11
Net income (loss) per share - diluted	$	(1.00	)	$	0.96	$	(2.36	)

Potential common shares of 8,564, 635, and 6,753 were excluded from the calculation of weighted average shares for the years ended December 31, 2016, 2015 and 2014, because their effect was considered to be anti-dilutive. For the years ended December 31, 2016 and 2014, the effects of dilutive securities were entirely excluded from the calculation of earnings per share as a net loss was reported in these periods.

Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive income (loss) for the twelve months ended December 31, net of immaterial tax effects:



Accumulated Other Comprehensive Income (Loss):	2016			2015			2014

Foreign currency translation adjustment:
Beginning balance	$	(22,312	)	$	(7,225	)	$	10,815
Net other comprehensive (loss) income	(1,024		)	(15,087		)	(18,040		)
Balance at December 31,	(23,336		)	(22,312		)	(7,225		)

Unrealized gain (loss) on marketable securities, net
Beginning balance	(345		)	(198		)	—
Net other comprehensive (loss) income, net of $16, ($20), ($0), tax, respectively	116			(147		)	(198		)
Balance at December 31,	(229		)	(345		)	(198		)
Accumulated other comprehensive loss at December 31,	$	(23,565	)	$	(22,657	)	$	(7,423	)

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Company Operations by Product, Customer and Geographic Area

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Company Operations by Product, Customer and Geographic Area

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary drug delivery technologies. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Company's Board of Directors review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.

The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Product:	2016		2015		2014

Bloxiverz	$	82,896	$	150,083	$	10,411
Vazculep	39,796		20,151		—
Akovaz	16,831		—		—
Other	7,699		2,054		1,782
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising the payer base. Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss.

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Significant Customer:	2016		2015		2014

Customer A	$	51,648	$	53,988	$	3,937
Customer B	39,359		60,420		3,859
Customer C	30,916		43,434		3,563
Customer D	17,728		—		—
Other	7,571		14,446		834
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

As of December 31, 2016, the Company had three customers each of which accounted for 10% or more of the accounts receivable balance. One customer accounted for 42%, or $7,472, a second customer accounted for 24% or $4,307, and a third customer accounted for 24% or $4,291. As of December 31, 2016, the Company had no significant past due account receivable balances.

The following table summarizes revenues by geographic region for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Geographic Region:	2016		2015		2014

United States	$	147,283	$	172,179	$	14,502
France	—		89		473
Ireland	2,963		741		—
Total	$	150,246	$	173,009	$	14,975

Currently we depend on a single contract manufacturing organization for the manufacture of Bloxiverz, Vazculep and Akovaz, and to deliver certain raw materials used in their production, from which we derive a majority of our revenues. Additionally, we purchase certain raw materials used in our products from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2016, 2015, and 2014:



Long-lived Assets by Geographic Region:	2016		2015		2014

United States	$	42,021	$	34,515	$	47,077
France	2,524		2,317		1,704
Ireland	202		258		—
Total	$	44,747	$	37,090	$	48,781

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

Discontinued Operations

12 Months Ended

Dec. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

On December 1, 2014, the Company signed an Asset Purchase Agreement with Recipharm AB (“Recipharm”) to divest its development and manufacturing facility and associated business located in Pessac, France. The assets included in the divestiture were tangible equipment, furniture and fixtures, inventories and all intellectual property rights relating to the operation and technological know-how necessary in manufacturing the products that are produced in the facility, as well as the assignment to Recipharm of all employees, customer contracts and liabilities which primarily relate to agreements of the Company with GlaxoSmithKline (“GSK”) for the manufacture and sale of Coreg CR®, which was Avadel’s lead product at the time, using its Micropump drug delivery platform and manufactured in the Pessac Facility.

The aggregate consideration received for the divested assets and business was $13,200, plus the value of divested inventory as determined using inventory valuation methodology as defined by the two parties. All cash and receivables pertaining to the Pessac Facility business prior to the sale were retained by the Company. A contribution of $700 was made by the Company to finance potential future retirement indemnities payable on transferred employees. The business was accounted for as a discontinued operation in the fourth quarter of 2014 and, therefore, the operating results of our Pessac Facility business were included in Discontinued Operations in the Company’s consolidated financial statements for all applicable years presented. The Company recognized a $5,007 gain on disposal, which was included in our income from Discontinued Operations, in fiscal year 2014. Concurrently with the above, Recipharm made an investment of $13,000 in newly issued Avadel (formerly Flamel) shares, the purchase price of which was based on the average of the trailing 20 days’ trading prices of the Company’s shares prior to the closing date.

In connection with the Asset Purchase Agreement, the Company also entered into a number of other agreements with Recipharm:

Master Agreement on Supply and Services of Products (“MSA”)

Recipharm will provide various services in the domain of R&D and manufacture of pharmaceutical products for an initial non-cancellable period of five years.

Over the initial term, any services to be provided shall include internal and external costs incurred by Recipharm plus 20%, which has been determined to be the fair value for such services. The minimum amount of services per year, for a cumulative total of $22,500 as follows:



Annual Service Minimum:	Amount

Year 1	$	4,250
Year 2	4,250
Year 3	4,250
Year 4	4,875
Year 5	4,875
Total	$	22,500

During the year ended December 31, 2016 and December 31, 2015, the Company recorded $4,541 and $4,089 of research and development expenses, and cash outflows of $939 and $5,679, related to this commitment to Recipharm.

Option Agreement

Recipharm has a first option (right of first refusal) to discuss and negotiate licenses of the Company’s intellectual property rights for the sale of certain products in Europe. Upon exercise of the option, Recipharm and the Company shall agree in good faith on terms and conditions of the related license agreement within forty-five (45) days from the exercise of the option. The term of the Option Agreement is from the signing of the agreement through December 31, 2017. The Company received no compensation related to the option agreement.

Summary results of operations for the divested Pessac business were as follows for the years ended December 31:



Net Income from Discontinued Operations:	2016		2015		2014

Revenues	$	—	$	—	$	14,967
Operating income (loss)	—		—		(875		)
Gain on disposal	—		—		5,007
Interest expense	—		—		(4		)
Income tax provision	—		—		(110		)
Net income from discontinued operations	$	—	$	—	$	4,018

The major cash flows related to Discontinued Operations as included in the consolidated statements of cash flows are as follows for the years ended December 31:



Cash Flow Related to Discontinued Operation:	2016		2015		2014

Capital expenditures	$	—	$	—	$	1,271
Depreciation and amortization	—		—		1,709
Operating and investing non-cash elements	—		—		(740		)

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65878427&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64862545&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64862545&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64827811&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=64827811&loc=SL51721683-107760

+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield Capital L.P (“Deerfield”), a significant shareholder of the Company. As of December 31, 2016 and 2015, the remaining consideration obligations for this transaction consisted of two warrants to purchase a total of 3,300 shares of Avadel and commitments to make earnout payments to Breaking Stick of 20% of any gross profit generated by certain Éclat products (the “Products”). Breaking Stick is majority owned by Deerfield, with a minority interest owned by Mr. Michael Anderson, the Company’s CEO, and certain other current and former employees. The original consideration for the acquisition of Éclat also included a $12 million senior note payable to the majority owners of Breaking Stick, which was fully repaid in March 2014 using the net proceeds from the Company’s public offering of ADS’s. As part of a February 2013 debt financing transaction conducted with Deerfield Management, Éclat entered into a Royalty Agreement with Horizon Santé FLML, Sarl and Deerfield Private Design Fund II, L.P., both affiliates of the Deerfield Entities (together, “Deerfield PDF/Horizon”). The Royalty Agreement provides for Éclat to pay Deerfield PDF/Horizon 1.75% of the net sales of the Products sold by the Company and any of its affiliates until December 31, 2024, with royalty payments accruing daily and paid in arrears for each calendar quarter during the term of the Royalty Agreement. The Company has also entered into a Security Agreement dated February 4, 2013 with Deerfield PDF/Horizon, whereby Deerfield PDF/Horizon was granted a security interest in the intellectual property and regulatory rights related to the Products to secure the obligations of Éclat and Avadel US Holdings, Inc., including the full and prompt payment of royalties to Deerfield PDF/Horizon under the Royalty Agreement. This original Deerfield debt financing transaction also included a $15 million facility agreement which was repaid in full in March 2014 using the net proceeds from the Company’s public offering of ADS’s. As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund (“Broadfin”), the Company entered into a Royalty Agreement with Broadfin, a significant shareholder of the Company, dated as of December 3, 2013 (the “Broadfin Royalty Agreement”). Pursuant to the Broadfin Royalty Agreement, the Company is required to pay a royalty of 0.834% on the net sales of certain products sold by the Company and any of its affiliates until December 31, 2024. This original Broadfin debt financing transaction also included a $5 million facility agreement which was repaid in full in March 2014 using the net proceeds from the Company’s public offering of ADS’s. On February 8, 2016, the Company entered into an agreement to acquire FSC Holdings, LLC (“FSC”), a Charlotte, NC-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients, from Deerfield CSF, LLC, a Deerfield Management company (“Deerfield”), a related party. Under the terms of the acquisition, which was completed on February 8, 2016, the Company will pay $1,050 annually for five years with a final payment in January 2021 of $15,000 for a total of $20,250 to Deerfield for all of the equity interests in FSC. The Company will also pay Deerfield a 15% royalty per annum on net sales of the current FSC products, up to $12,500 for a period not exceeding ten years.

Subsequent Event	12 Months Ended
Subsequent Event	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event In preparing these consolidated financial statements, subsequent events were evaluated through the time the financial statements were issued. Financial statements are considered issued when they are widely distributed to all stockholders and other financial statement users, or filed with the SEC. In March 2017, the Board of Directors approved an authorization to repurchase up to $25,000 of Avadel ordinary shares represented by American Depository Receipts in the open market with an indefinite duration. The timing and amount of repurchases, if any, will depend on a variety of factors, including the price of our shares, cash resources, alternative investment opportunities, corporate and regulatory requirements and market conditions. This share repurchase program may be modified, suspended or discontinued at any time without prior notice. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program.

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2016

Valuation and Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts Disclosure

Schedule II

Valuation and Qualifying Accounts

(In thousands)



Deferred Tax Asset Valuation Allowance:	Balance, Beginning of Period		Additions (a)		Deductions (b)			Other Changes (c)			Balance, End of Period

2016	$	45,516	$	6,873	$	(42,417	)	$	(2,373	)	$	7,599
2015	57,980		4,312		(11,737		)	(5,039		)	45,516
2014	69,939		8,453		(13,185		)	(7,227		)	57,980


a.	Additions to the deferred tax asset valuation allowance relate to movements on certain French, Irish and U.S. deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.


b.	Deductions to the deferred tax asset valuation allowance include movements relating to utilization and removal of net operating losses and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.


c.	Other changes to the deferred tax asset valuation allowance relate primarily to currency translation adjustments recorded directly in equity.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Nature of Operations

•


•	Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel.


•	our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each


◦	all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital

◦


•	all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company.

Basis of Presentation

Reclassifications and Immaterial Corrections of Prior Period Amounts

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Twelve Months Ended December 31, 2014
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(b)		(f)			As revised

Product sales and services	$	11,993		$	200	$	—		$	12,193
Total revenue	14,775			200		—			14,975
Operating income (loss)	(93,857		)	200		—			(93,657		)
Income (loss) before income taxes	(90,331		)	200		—			(90,131		)
Income tax provision (benefit)	(1,407		)	70		693			(644		)
Net income (loss) from continuing operations	(88,924		)	130		(693		)	(89,487		)
Net income (loss)	(84,906		)	130		(693		)	(85,469		)
Net loss per share - basic	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)
Net loss per share - diluted	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)



	Twelve Months Ended December 31, 2015
			Correction of Immaterial Errors
Consolidated Statement of Income:	As filed		(a)			(b)			(c)			As revised

Product sales and services	$	172,488	$	—		$	(200	)	$	—		$	172,288
Total revenue	173,209		—			(200		)	—			173,009
Cost of products and services sold	10,921		—			—			489			11,410
Total operating expenses	101,762		—			—			489			102,251
Operating income (loss)	71,447		—			(200		)	(489		)	70,758
Income (loss) before income taxes	78,394		—			(200		)	(489		)	77,705
Income tax provision (benefit)	37,735		(1,587		)	(70		)	(171		)	35,907
Net income (loss) from continuing operations	40,659		1,587			(130		)	(318		)	41,798
Net income (loss)	40,659		1,587			(130		)	(318		)	41,798
Net income (loss) per share - basic	$	1.00	$	0.04		$	—		$	(0.01	)	1.03
Net income (loss) per share - diluted	$	0.93	$	0.04		$	—		$	(0.01	)	$	0.96



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(c)			(d)			(e)			(g)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(228		)	(171		)	—			—			76		—
Total current liabilities	48,788			(228		)	(171		)	(3,410		)	193			76		45,248
Long-term related party payable	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,359		)	—			—			—			8		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)


(c)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(d)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(e)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(f)


(g)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (f) above.

Revenue

Revenue includes sales of pharmaceutical products, amortization of licensing fees and, if any, milestone payments for R&D achievements.

Product Sales and Services

License and Research Revenue

Governmental Grants

Government Grants

The Company receives financial support for various research or investment projects from governmental agencies.

Research and Development

The Company recognizes R&D tax credits received from the French government for spending on innovative R&D as an offset of R&D expenses.

Stock-based Compensation

Income Taxes

Discontinued Operations

Cash and Cash Equivalents

Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.

Marketable Securities

Accounts Receivables

Accounts Receivable

Inventories

Property and Equipment

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:



Laboratory equipment	4-8 years
Office and computer equipment	3 years
Leasehold improvements, furniture, fixtures and fittings	5-10 years

Goodwill

Long-Lived Assets

Financing-related Royalty Agreements

Foreign Currency Translation

Use of Estimates

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of Error Corrections and Prior Period Adjustments

The impact of the above errors and reclassifications on previously presented line items for each comparative period presented is as follows:



	Twelve Months Ended December 31, 2014
				Correction of Immaterial Errors
Consolidated Statement of Loss:	As filed			(b)		(f)			As revised

Product sales and services	$	11,993		$	200	$	—		$	12,193
Total revenue	14,775			200		—			14,975
Operating income (loss)	(93,857		)	200		—			(93,657		)
Income (loss) before income taxes	(90,331		)	200		—			(90,131		)
Income tax provision (benefit)	(1,407		)	70		693			(644		)
Net income (loss) from continuing operations	(88,924		)	130		(693		)	(89,487		)
Net income (loss)	(84,906		)	130		(693		)	(85,469		)
Net loss per share - basic	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)
Net loss per share - diluted	$	(2.34	)	$	—	$	(0.02	)	$	(2.36	)



	Twelve Months Ended December 31, 2015
			Correction of Immaterial Errors
Consolidated Statement of Income:	As filed		(a)			(b)			(c)			As revised

Product sales and services	$	172,488	$	—		$	(200	)	$	—		$	172,288
Total revenue	173,209		—			(200		)	—			173,009
Cost of products and services sold	10,921		—			—			489			11,410
Total operating expenses	101,762		—			—			489			102,251
Operating income (loss)	71,447		—			(200		)	(489		)	70,758
Income (loss) before income taxes	78,394		—			(200		)	(489		)	77,705
Income tax provision (benefit)	37,735		(1,587		)	(70		)	(171		)	35,907
Net income (loss) from continuing operations	40,659		1,587			(130		)	(318		)	41,798
Net income (loss)	40,659		1,587			(130		)	(318		)	41,798
Net income (loss) per share - basic	$	1.00	$	0.04		$	—		$	(0.01	)	1.03
Net income (loss) per share - diluted	$	0.93	$	0.04		$	—		$	(0.01	)	$	0.96



	December 31, 2015
				Correction of Immaterial Errors									Reclassifications
Consolidated Balance Sheet:	As filed			(a)			(c)			(d)			(e)			(g)		As revised

Accounts receivable	$	6,978		$	—		$	—		$	—		$	509		$	—	$	7,487
Inventories	4,155			—			(489		)	—			—			—		3,666
Prepaid expenses and other current assets	7,989			—			—			—			—			75		8,064
Total current assets	166,306			—			(489		)	—			509			75		166,401
Other	158			—			—			—			—			9		167
Total assets	214,977			—			(489		)	—			509			84		215,081
Current portion of long-term related party payable	28,614			—			—			(3,410		)	—			—		25,204
Accounts payable	10,565			—			—			—			(5,517		)	—		5,048
Accrued expenses	3,598			—			—			—			5,710			—		9,308
Income taxes	323			(228		)	(171		)	—			—			76		—
Total current liabilities	48,788			(228		)	(171		)	(3,410		)	193			76		45,248
Long-term related party payable	94,079			—			—			3,410			—			—		97,489
Deferred taxes	1,351			(1,359		)	—			—			—			8		—
Other	2,210			—			—			—			316			—		2,526
Total liabilities	147,112			(1,587		)	(171		)	—			509			84		145,947
Accumulated deficit	(279,793		)	1,587			(318		)	—			—			—		(278,524		)
Total shareholders' equity	67,865			1,587			(318		)	—			—			—		69,134
Total liabilities and shareholders' equity	214,977			—			(489		)	—			509			84		215,081


(a)	Reflects the cumulative 2015 correction of $1,587 of income tax benefits related to the deductibility of the U.S. Internal Revenue Code Section 483 imputed interest on contingent consideration liabilities which should have been recorded in prior periods ($866, $292, $863 and ($434) in the first, second, third and fourth quarters of 2015, respectively).

(b)


(c)	Reflects the correction of a $489 error in the Company’s inventory obsolescence reserve accrual and expense which was originally recorded in the first quarter of 2016 but should have been recorded in the fourth quarter of 2015.


(d)	Reflects the correction of a balance sheet classification error which overstated the current portion of the long-term related party payable by $3,410.


(e)	Reflects revisions to the presentation of certain gross to net revenue reserves which were previously included in accounts payable and are now included in accrued expenses.

(f)


(g)	Reflects balance sheet reclassifications required to properly net the accrued income tax and deferred income tax amounts within the balance sheet as a result of the adjustments made in items (a) through (f) above.

Schedule of Property and Equipment Useful Life

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:



Laboratory equipment	4-8 years
Office and computer equipment	3 years
Leasehold improvements, furniture, fixtures and fittings	5-10 years

The principal categories of property and equipment, net at December 31, 2016 and 2015, respectively, are as follows:



Property and Equipment, net:	2016			2015

Laboratory equipment	$	9,019		$	9,963
Office and computer equipment	2,519			2,968
Furniture, fixtures and fittings	4,239			4,315
Less - accumulated depreciation	(12,457		)	(14,630		)
Total	$	3,320		$	2,616

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis



	As of December 31, 2016						As of December 31, 2015
Fair Value Measurements:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3

Marketable securities (see Note 4)
Equity securities	$	4,033	$	—	$	—	$	3,525	$	—	$	—
Time deposits	—		—		—		—		13,641		—
Corporate bonds	—		57,348		—		—		42,139		—
Government securities - U.S.	—		42,814		—		—		13,738		—
Government securities - Non-U.S.	—		233		—		—		1,063		—
Other fixed-income securities	—		10,471		—		—		3,992		—
Other securities	—		81		—		—		1,640		—
Total assets	$	4,033	$	110,947	$	—	$	3,525	$	76,213	$	—

Related party payable (see Note 10)	—		—		169,347		—		—		122,693
Total liabilities	$	—	$	—	$	169,347	$	—	$	—	$	122,693

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2016

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale Securities



	2016
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	3,689	$	409	$	(65	)	$	4,033
Corporate bonds	57,871		89		(612		)	57,348
Government securities - U.S.	43,049		515		(750		)	42,814
Government securities - Non-U.S.	247		—		(14		)	233
Other fixed-income securities	10,281		221		(31		)	10,471
Other securities	81		—		—			81
Total	$	115,218	$	1,234	$	(1,472	)	$	114,980



	2015
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	3,510	$	29	$	(14	)	$	3,525
Time deposits	13,641		—		—			13,641
Corporate bonds	42,129		1,520		(1,510		)	42,139
Government securities - U.S.	13,822		4		(88		)	13,738
Government securities - Non-U.S.	1,112		8		(57		)	1,063
Other fixed-income securities	4,008		—		(16		)	3,992
Other securities	1,663		—		(23		)	1,640
Total	$	79,885	$	1,561	$	(1,708	)	$	79,738

Investments Classified by Contractual Maturity Date



	Maturities
Marketable Securities:	Less than 1 Year		1-5 Years		5-10 Years		Greater than 10 Years		Total

Equity securities	$	4,033	$	—	$	—	$	—	$	4,033
Corporate bonds	11,933		39,325		5,655		435		57,348
Government securities - U.S.	2,258		33,270		1,530		5,756		42,814
Government securities - Non-U.S.	—		—		233		—		233
Other fixed-income securities	—		8,199		1,996		276		10,471
Other securities	81		—		—		—		81
Total	$	18,305	$	80,794	$	9,414	$	6,467	$	114,980

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Inventory (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventory

The principal categories of inventories, net reserves of $3,223 and $806 in 2016 and 2015, respectively, are comprised of the following as of December 31:



Inventory:	2016		2015

Finished goods	$	2,429	$	2,545
Raw materials	829		1,121
Total	$	3,258	$	3,666

Property and Equipment, net (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:



Laboratory equipment	4-8 years
Office and computer equipment	3 years
Leasehold improvements, furniture, fixtures and fittings	5-10 years

The principal categories of property and equipment, net at December 31, 2016 and 2015, respectively, are as follows:



Property and Equipment, net:	2016			2015

Laboratory equipment	$	9,019		$	9,963
Office and computer equipment	2,519			2,968
Furniture, fixtures and fittings	4,239			4,315
Less - accumulated depreciation	(12,457		)	(14,630		)
Total	$	3,320		$	2,616

Acquisitions (Tables)

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The Company finalized its purchase price allocation as noted in the following table. The fair values assigned to the acquired assets and liabilities have been recognized as follows:



	2016
Assigned Fair Value:	Final

Accounts receivable	$	142
Inventories	1,135
Prepaid expenses and other current assets	1,712
Intangible assets:
Acquired product marketing rights	16,600
Acquired developed technology	4,300
Deferred tax assets	853
Other assets	277
Accounts payable and other liabilities	(3,827		)
Total	$	21,192

Business Acquisition, Pro Forma Information



Pro Forma Net Revenue and Income (Losses):	2016			2015

Net revenues	$	150,721		$	178,104
Net income (loss)	(42,290		)	30,965

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill

The Company's amortizable and unamortizable intangible assets at December 31, 2016 and 2015, respectively, are as follows:



	2016							2015
Goodwill and Intangible Assets:	Gross Value		Accumulated Amortization			Net Book Value		Gross Value		Accumulated Amortization			Net Book Value

Amortizable intangible assets:
Acquired IPR&D - Bloxiverz	$	35,248	$	(35,248	)	$	—	$	35,248	$	(23,498	)	$	11,750
Acquired IPR&D - Vazculep	12,061		(8,801		)	3,260		12,061		(7,986		)	4,075
Acquired product marketing rights	16,600		(1,019		)	15,581		—		—			—
Acquired developed technology	4,300		(304		)	3,996		—		—			—
Total amortizable intangible assets	$	68,209	$	(45,372	)	$	22,837	$	47,309	$	(31,484	)	$	15,825

Unamortizable intangible assets:
Goodwill	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491
Total unamortizable intangible assets	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Total future amortization of intangible assets for the next five years is as follows:



Estimated Amortization Expense:	Balance

2017	$	2,258
2018	2,258
2019	2,258
2020	2,258
2021	1,443

Long-Term Related Party Payable (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Schedule of Related Party Transactions

Long-term related party payable and related activity are reported at fair value and consist of the following at December 31, 2016 and 2015, respectively:



				Activity during the Twelve Months Ended December 31, 2016
									Changes in Fair Value of Related Party Payable
	Balance, December 31, 2015			Additions		Payments to Related Parties			Operating Expense			Other Expense		Balance, December 31, 2016

Acquisition-related:
Warrants - Éclat Pharmaceuticals ^(a)	$	20,617		$	—	$	—		$	(9,400	)	$	—	$	11,217
Earn-out payments - Éclat Pharmaceuticals ^(b)	90,468			—		(26,700		)	57,609			—		121,377
Royalty agreement - FSC ^(c)	—			6,659		(444		)	1,076			—		7,291
Financing-related:														—
Royalty agreement - Deerfield ^(d)	7,862			—		(2,501		)	—			4,433		9,794
Royalty agreement - Broadfin ^(e)	3,746			—		(1,193		)	—			2,115		4,668
Long-term liability - FSC ^(f)	—			15,000		—			—			—		15,000
Total related party payable	122,693			$	21,659	$	(30,838	)	$	49,285		$	6,548	169,347
Less: current portion	(25,204		)											(34,177		)
Total long-term related party payable	$	97,489												$	135,170

Each of the above items is associated with related parties as further described in Note 20: Related Party Transactions.

(a)

The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the twelve-month periods ended December 31, 2016, 2015 and 2014:



Related Party Payable:	Balance

Balance at December 31, 2013	65,670
Payment of related party payable	(11,936	)
Fair value adjustments ⁽¹⁾	61,016
Balance at December 31, 2014	114,750
Payment of related party payable	(27,897	)
Fair value adjustments ⁽¹⁾	35,840
Balance at December 31, 2015	122,693
Additions ⁽²⁾	21,659
Payment of related party payable	(30,838	)
Fair value adjustments ⁽¹⁾	55,833
Balance at December 31, 2016	169,347

⁽²⁾Relates to the acquisition of FSC. See items (c) and (f) above.

(b)


(c)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.


(d)	As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024.


(e)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.


(f)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000.

Schedule Of Fair Value Assumptions Of Warrant

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of December 31, 2016 and 2015:



Warrant Assumptions:	2016			2015

Weighted average exercise price per share	$	8.63		$	8.63
Expected term (years)	1.25			2.25
Expected volatility	54.20		%	64.54		%
Risk-free interest rate	0.94		%	0.93		%
Expected dividend yield	—			—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule Of Components Of Income Before Income Tax

The components of income (loss) before income taxes for the years ended December 31, are as follows:



Income (Loss) Before Income Taxes:	2016			2015			2014

Ireland	$	(22,866	)	$	(29,469	)	$	—
United States	32,786			100,552			(89,739		)
France	(19,638		)	6,622			(392		)
Total income (loss) before income taxes	$	(9,718	)	$	77,705		$	(90,131	)

Schedule Of Income Tax Payments

The income tax provision (benefit) for the years ended December 31, is as follows:



Income Tax Provision (Benefit):	2016			2015			2014

Current:
United States - Federal	$	30,738		$	33,289		$	—
United States - State	1,081			970			—
France	5,267			1,657			1,400
Total current	37,086			35,916			1,400

Deferred:
United States - Federal	(6,443		)	504			(1,713		)
United States - State	(23		)	1,234			(331		)
France	938			(1,747		)	—
Total deferred	(5,528		)	(9		)	(2,044		)

Income tax provision (benefit)	$	31,558		$	35,907		$	(644	)

Schedule of Effective Income Tax Rate Reconciliation



Reconciliation to Effective Income Tax Rate:	2016			2015			2014

Statutory tax rate ⁽¹⁾	12.5		%	33.3		%	33.3		%
Non-deductible changes in fair value of contingent consideration	(165.0		)%	11.9		%	(24.8		)%
Change in valuation allowance	11.8		%	(9.6		)%	5.3		%
Income tax deferred charge	(9.7		)%	1.3		%	(16.9		)%
International tax rates differential	(31.9		)%	11.0		%	6.7		%
Nondeductible stock based compensation	(14.8		)%	1.3		%	(0.8		)%
Cross-border merger	(100.6		)%	—		%	—		%
Unrecognized tax benefit	(15.2		)%	0.4		%	—		%
State and local taxes (net of federal)	(9.6		)%	1.5		%	0.3		%
Other	(2.3		)%	(4.9		)%	(2.3		)%
Effective income tax rate	(324.8		)%	46.2		%	0.8		%

Income tax provision (benefit) - at statutory tax rate	$	(1,215	)	$	25,876		$	(30,013	)
Non-deductible changes in fair value of contingent consideration	16,036			9,249			22,326
Change in valuation allowance	(1,143		)	(7,425		)	(4,732		)
Income tax deferred charge	938			980			15,273
International tax rates differential	3,097			8,547			(6,023		)
Nondeductible stock based compensation	1,436			1,004			693
Cross-border merger	9,773			—			—
Unrecognized tax benefit	1,475			290			—
State and local taxes (net of federal)	934			1,170			(228		)
Other	227			(3,784		)	2,060
Income tax provision (benefit) - at effective income tax rate	$	31,558		$	35,907		$	(644	)

⁽¹⁾ The statutory rate reflects the Irish statutory tax rate of 12.5% for fiscal 2016, and the French statutory tax rate of 33.3% for fiscal 2015 and 2014.

Summary of Unrecognized Tax Benefits

The following table summarizes the activity related to the Company's unrecognized tax benefits for the twelve months ended December 31:



Unrecognized Tax Benefit Activity	2016			2015		2014

Balance at January 1:	$	448		$	—	$	—
Additions based on tax positions related to the current year	1,578			448		—
Additions (reductions) for tax positions of prior years	(340		)	—		—
Statute of limitations expiration	—			—		—
Settlements	—			—		—
Balance at December 31:	$	1,686		$	448	$	—

Schedule of Deferred Tax Assets and Liabilities

The net deferred tax assets/liabilities at December 31, 2016 and 2015 resulted from the following temporary differences:



Net Deferred Tax Assets and Liabilities:	2016			2015

Deferred tax assets:
Net operating loss carryforwards	$	11,566		$	44,587
Stock based compensation	5,012			1,767
Fair value royalty agreements	3,386			2,435
Fair value contingent consideration	2,152			1,348
Other	583			1,037
Total deferred tax assets	22,699			51,174
Valuation allowances	(7,599		)	(45,516		)
Net deferred tax assets	15,100			5,658

Deferred tax liabilities:
Amortization	(4,349		)	(5,649		)
Accounts receivable	(3,319		)	—
Total deferred tax liabilities	(7,668		)	(5,649		)

Net deferred tax assets	$	7,432		$	9

Post-Retirement Benefit Plans (Tables)

12 Months Ended

Dec. 31, 2016

Compensation and Retirement Disclosure [Abstract]

Schedule Of Defined Benefit Plan Assumptions

The benefit obligation is calculated as the present value of estimated future benefits to be paid, using the following assumptions for the years ended December 31:



Retirement Benefit Obligation Assumptions:	2016		2015		2014

Compensation rate increase	3.00	%	3.00	%	3.00	%
Discount rate	1.31	%	2.03	%	1.49	%
Employee turn-over	Actuarial standard and average of the last 5 years
Average age of retirement	60 to 65 years actuarial standard based on age and professional status

Schedule of Changes in Accumulated Postemployment Benefit Obligations

Changes in the funded status of the retirement indemnity benefit plans were as follows for the years ended December 31:



Retirement Benefit Obligation Activity:	2016			2015

Retirement indemnity benefit obligation, beginning of year	$	2,170		$	2,350
Service cost	123			117
Interest cost	29			20
Benefits paid	—			(46		)
Actuarial loss (gain)	203			(27		)
Exchange rate changes	(94		)	(244		)
Retirement indemnity benefit obligation, end of year	$	2,431		$	2,170

Schedule Of Defined Benefit Plan Expected Future Benefit

The future expected benefits to be paid over the next five years and for the five years thereafter is as follows for the years ended December 31:



Future Retirement Indemnity Benefit Obligation:	Balance

2017	$	—
2018	—
2019	11
2020	—
2021	—
Next five years	1,061
Total	1,072

Other Assets and Liabilities (Tables)

12 Months Ended

Dec. 31, 2016

Other Liabilities Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Various other assets and liabilities are summarized as follows for the years ending December 31, is as follows:



Prepaid Expenses and Other Current Assets:	2016		2015

Valued-added tax recoverable	$	736	$	1,099
Prepaid expenses	3,442		2,921
Advance to suppliers and other current assets	1,265		518
Income tax receivable	451		3,526
Total	$	5,894	$	8,064

Schedule of Other Non-Current Assets



Other Non-Current Assets:	2016		2015

Deferred tax assets	$	7,432	$	9
Other	99		158
Total	$	7,531	$	167

Schedule of Accrued Expenses



Accrued Expenses	2016		2015

Accrued compensation	$	3,291	$	1,888
Accrued social charges	794		1,710
Customer allowances	7,981		5,710
Accrued contract research organization	1,764		—
Other	3,392		—
Total	$	17,222	$	9,308

Schedule of Other Non-Current Liabilities



Other Non-Current Liabilities	2016		2015

Provision for retirement indemnity	$	2,431	$	2,170
Customer allowances	905		—
Unrecognized tax benefits	1,565		291
Other	374		65
Total	$	5,275	$	2,526

Contingent Liabilities and Commitments (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Contractual Obligation, Fiscal Year Maturity Schedule



Purchase Commitment:	Balance

2017	$	778
2018	1,032
2019	1,126
2020	1,126
2021	1,126
Thereafter	15,295
Total	$	20,483

The following table presents contractual obligations of the Company at December 31, 2016:



	Payments Due by Period
Contractual Obligations:	Total		Less than 1 Year		1 to 3 Years		3 to 5 Years		More than 5 Years

Long-term debt	$	815	$	268	$	547	$	—	$	—
Long-term related party payable (undiscounted)	278,236		35,226		57,466		60,587		124,957
Purchase commitments	41,721		12,266		11,908		2,252		15,295
Operating leases	4,982		1,390		1,837		1,155		600
Total contractual cash obligations	$	325,754	$	49,150	$	71,758	$	63,994	$	140,852

Schedule of Future Minimum Rental Payments for Operating Leases



Lease Commitment:	Balance

2017	$	1,117
2018	783
2019	717
2020	699
2021	441
Thereafter	600
Total	$	4,357

Equity Instruments and Stock Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Compensation expense included in the Company’s consolidated statements of income (loss) for all stock-based compensation arrangements was as follows for the periods ended December 31:



Stock-based Compensation Expense:	2016		2015		2014

Cost of products and services sold	$	—	$	—	$	38
Research and development	3,523		1,587		1,027
Selling, general and administrative	11,156		6,154		1,829
Total stock-based compensation expense	$	14,679	$	7,741	$	2,894

Schedule Of Share Based Payment Award Stock Options And Warrant Grants Valuation Assumptions

The weighted-average assumptions under the Black-Scholes option-pricing model for stock option and warrant grants as of December 31, 2016, 2015 and 2014, are as follows:



Stock Option and Warrant Assumptions:	2016		2015		2014

Stock option grants:
Expected term (years)	6.25		6.25		6.25
Expected volatility	58.39	%	58.59	%	59.00	%
Risk-free interest rate	2.04	%	1.89	%	1.79	%
Expected dividend yield	—		—		—

Warrant grants:
Expected term (years)	2.50		2.50		2.50
Expected volatility	60.57	%	55.00	%	58.00	%
Risk-free interest rate	0.82	%	0.89	%	0.75	%
Expected dividend yield	—		—		—

Schedule of Share-based Compensation, Stock Options, Activity

A summary of the combined stock option activity and other data for the Company's stock option plans for the year ended December 31, 2016 is as follows:



Stock Option Activity and Other Data:	Number of Stock Options		Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

Stock options outstanding, January 1, 2016	2,326		$	13.84
Granted	1,505		10.68
Exercised	(15	)	6.50
Forfeited	(6	)	14.35
Expired	(78	)	31.70
Stock options outstanding, December 31, 2016	3,732		$	12.07	8.48 years	$	3,681
Stock options exercisable, December 31, 2016	1,161		$	10.49	6.76 years	$	3,035

Schedule of Stockholders' Equity Note, Warrants or Rights

A summary of the combined warrant activity and other data for the year ended December 31, 2016 is as follows:



Warrant Activity and Other Data:	Number of Warrants	Weighted Average Exercise Price per Share		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

Warrants outstanding, January 1, 2016	668	$	16.97
Granted	291	13.59
Exercised	—	—
Forfeited	—	—
Expired	—	—
Warrants outstanding, December 31, 2016	959	$	16.05	2.47 years	$	276
Warrants exercisable, December 31, 2016	668	$	17.12	1.97 years	$	276

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award

A summary of the Company's free share awards as of December 31, 2016, and changes during the year then ended, is reflected in the table below.



Free Share Activity and Other Data:	Number of Free Share Awards		Weighted Average Grant Date Fair Value

Non-vested free share awards outstanding, January 1, 2016	226		$	13.95
Granted	463		12.11
Vested	(115	)	13.44
Forfeited	(1	)	16.27
Non-vested free shares awards outstanding, December 31, 2016	573		$	12.57

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Earnings (Loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2016

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

A reconciliation of basic and diluted earnings (loss) per share, together with the related shares outstanding in thousands for the years ended December 31, is as follows:



Basic and Diluted Earnings (Loss) Per Share:	2016			2015		2014

Net income (loss)
Net income (loss) from continuing operations	$	(41,276	)	$	41,798	$	(89,487	)
Net income (loss) from discontinued operations	—			—		4,018
Net income (loss)	$	(41,276	)	$	41,798	$	(85,469	)

Weighted average shares:
Basic shares	41,248			40,580		36,214
Effect of dilutive securities—options and warrants outstanding	—			3,039		—
Diluted shares	41,248			43,619		36,214

Earnings (loss) per share - basic:
Continuing operations	$	(1.00	)	$	1.03	$	(2.47	)
Discontinued operations	—			—		0.11
Net income (loss) per share - basic	$	(1.00	)	$	1.03	$	(2.36	)

Earnings (loss) per share - diluted:
Continuing operations	$	(1.00	)	$	0.96	$	(2.47	)
Discontinued operations	—			—		0.11
Net income (loss) per share - diluted	$	(1.00	)	$	0.96	$	(2.36	)

Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive income (loss) for the twelve months ended December 31, net of immaterial tax effects:



Accumulated Other Comprehensive Income (Loss):	2016			2015			2014

Foreign currency translation adjustment:
Beginning balance	$	(22,312	)	$	(7,225	)	$	10,815
Net other comprehensive (loss) income	(1,024		)	(15,087		)	(18,040		)
Balance at December 31,	(23,336		)	(22,312		)	(7,225		)

Unrealized gain (loss) on marketable securities, net
Beginning balance	(345		)	(198		)	—
Net other comprehensive (loss) income, net of $16, ($20), ($0), tax, respectively	116			(147		)	(198		)
Balance at December 31,	(229		)	(345		)	(198		)
Accumulated other comprehensive loss at December 31,	$	(23,565	)	$	(22,657	)	$	(7,423	)

Company Operations by Product, Customer and Geographic Area (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Revenue from External Customers by Product and Services

The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Product:	2016		2015		2014

Bloxiverz	$	82,896	$	150,083	$	10,411
Vazculep	39,796		20,151		—
Akovaz	16,831		—		—
Other	7,699		2,054		1,782
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

Schedule of Revenue by Major Customers by Reporting Segments

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Significant Customer:	2016		2015		2014

Customer A	$	51,648	$	53,988	$	3,937
Customer B	39,359		60,420		3,859
Customer C	30,916		43,434		3,563
Customer D	17,728		—		—
Other	7,571		14,446		834
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

Revenue from External Customers by Geographic Areas

The following table summarizes revenues by geographic region for the twelve months ended December 31, 2016, 2015, and 2014:



Revenue by Geographic Region:	2016		2015		2014

United States	$	147,283	$	172,179	$	14,502
France	—		89		473
Ireland	2,963		741		—
Total	$	150,246	$	173,009	$	14,975

Long-lived Assets by Geographic Areas

The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2016, 2015, and 2014:



Long-lived Assets by Geographic Region:	2016		2015		2014

United States	$	42,021	$	34,515	$	47,077
France	2,524		2,317		1,704
Ireland	202		258		—
Total	$	44,747	$	37,090	$	48,781

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2016

Discontinued Operations and Disposal Groups [Abstract]

Schedule Of Supply And Services Of Products

The minimum amount of services per year, for a cumulative total of $22,500 as follows:



Annual Service Minimum:	Amount

Year 1	$	4,250
Year 2	4,250
Year 3	4,250
Year 4	4,875
Year 5	4,875
Total	$	22,500

Schedule Of Disposal Groups, Including Discontinued Operation Income Statement

Summary results of operations for the divested Pessac business were as follows for the years ended December 31:



Net Income from Discontinued Operations:	2016		2015		2014

Revenues	$	—	$	—	$	14,967
Operating income (loss)	—		—		(875		)
Gain on disposal	—		—		5,007
Interest expense	—		—		(4		)
Income tax provision	—		—		(110		)
Net income from discontinued operations	$	—	$	—	$	4,018

Schedule Of Disposal Groups, Including Discontinued Operation Cash Flows

The major cash flows related to Discontinued Operations as included in the consolidated statements of cash flows are as follows for the years ended December 31:



Cash Flow Related to Discontinued Operation:	2016		2015		2014

Capital expenditures	$	—	$	—	$	1,271
Depreciation and amortization	—		—		1,709
Operating and investing non-cash elements	—		—		(740		)

Summary of Significant Accounting Policies - Income Statement Restatements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services					$ 147,222	$ 172,288	$ 12,193
Total revenues					150,246	173,009	14,975
Cost of products and services sold					13,248	11,410	3,383
Total operating expenses					155,211	102,251	108,632
Operating income (loss)					(4,965)	70,758	(93,657)
Income (loss) before income taxes					(9,718)	77,705	(90,131)
Income tax provision (benefit)					31,558	35,907	(644)
Net income (loss) from continuing operations					(41,276)	41,798	(89,487)
Net income (loss)					$ (41,276)	$ 41,798	$ (85,469)
Net income (loss) per share - basic (in usd per share)					$ (1.00)	$ 1.03	$ (2.36)
Net income (loss) per share - diluted (in usd per share)					$ (1.00)	$ 0.96	$ (2.36)
As Filed
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services						$ 172,488	$ 11,993
Total revenues						173,209	14,775
Cost of products and services sold						10,921
Total operating expenses						101,762
Operating income (loss)						71,447	(93,857)
Income (loss) before income taxes						78,394	(90,331)
Income tax provision (benefit)						37,735	(1,407)
Net income (loss) from continuing operations						40,659	(88,924)
Net income (loss)						$ 40,659	$ (84,906)
Net income (loss) per share - basic (in usd per share)						$ 1.00	$ (2.34)
Net income (loss) per share - diluted (in usd per share)						$ 0.93	$ (2.34)
(a) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services						$ 0
Total revenues						0
Cost of products and services sold						0
Total operating expenses						0
Operating income (loss)						0
Income (loss) before income taxes						0
Income tax provision (benefit)	$ 434	$ (863)	$ (292)	$ (866)		(1,587)
Net income (loss) from continuing operations						1,587
Net income (loss)						$ 1,587
Net income (loss) per share - basic (in usd per share)						$ 0.04
Net income (loss) per share - diluted (in usd per share)						$ 0.04
(b) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services						$ (200)	$ 200
Total revenues				200		(200)	200
Cost of products and services sold						0
Total operating expenses						0
Operating income (loss)						(200)	200
Income (loss) before income taxes						(200)	200
Income tax provision (benefit)						(70)	70
Net income (loss) from continuing operations						(130)	130
Net income (loss)						$ (130)	$ 130
Net income (loss) per share - basic (in usd per share)						$ 0.00	$ 0.00
Net income (loss) per share - diluted (in usd per share)						$ 0.00	$ 0.00
(c) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services						$ 0
Total revenues						0
Cost of products and services sold						489
Total operating expenses						489
Operating income (loss)						(489)
Income (loss) before income taxes						(489)
Income tax provision (benefit)						(171)
Net income (loss) from continuing operations						(318)
Net income (loss)						$ (318)
Net income (loss) per share - basic (in usd per share)						$ (0.01)
Net income (loss) per share - diluted (in usd per share)						$ (0.01)
(f) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Product sales and services							$ 0
Total revenues							0
Operating income (loss)							0
Income (loss) before income taxes							0
Income tax provision (benefit)	$ (2,606)	$ (750)	$ (1,026)	$ (830)			693	$ (333)	$ (360)
Net income (loss) from continuing operations							(693)
Net income (loss)							$ (693)
Net income (loss) per share - basic (in usd per share)							$ (0.02)
Net income (loss) per share - diluted (in usd per share)							$ (0.02)

Summary of Significant Accounting Policies - Balance Sheet Restatements and Reclassifications (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable	$ 17,839		$ 7,487
Inventories	3,258		3,666
Prepaid expenses and other current assets	5,894		8,064
Total current assets	181,186		166,401
Other	7,531		167
Total assets	245,482		215,081
Current portion of long-term related party payable	34,177		25,204
Accounts payable	7,105		5,048
Accrued expenses	17,222		9,308
Income taxes	1,200		0
Total current liabilities	62,421		45,248
Long-term related party payable	135,170		97,489
Deferred taxes			0
Other	5,275		2,526
Total liabilities	203,413		145,947
Accumulated deficit	(319,800)		(278,524)
Total shareholders' equity	42,069		69,134	$ 25,025	$ (8,819)
Total liabilities and shareholders' equity	$ 245,482		215,081
As Filed
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			6,978
Inventories			4,155
Prepaid expenses and other current assets			7,989
Total current assets			166,306
Other			158
Total assets			214,977
Current portion of long-term related party payable			28,614
Accounts payable			10,565
Accrued expenses			3,598
Income taxes			323
Total current liabilities			48,788
Long-term related party payable			94,079
Deferred taxes			1,351
Other			2,210
Total liabilities			147,112
Accumulated deficit			(279,793)
Total shareholders' equity			67,865
Total liabilities and shareholders' equity			214,977
(e)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			509
Inventories			0
Prepaid expenses and other current assets			0
Total current assets			509
Other			0
Total assets			509
Current portion of long-term related party payable			0
Accounts payable			(5,517)
Accrued expenses			5,710
Income taxes			0
Total current liabilities			193
Long-term related party payable			0
Deferred taxes			0
Other			316
Total liabilities			509
Accumulated deficit			0
Total shareholders' equity			0
Total liabilities and shareholders' equity			509
(g)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			0
Inventories			0
Prepaid expenses and other current assets			75
Total current assets			75
Other			9
Total assets			84
Current portion of long-term related party payable			0
Accounts payable			0
Accrued expenses			0
Income taxes			76
Total current liabilities			76
Long-term related party payable			0
Deferred taxes			8
Other			0
Total liabilities			84
Accumulated deficit			0
Total shareholders' equity			0
Total liabilities and shareholders' equity			84
(a) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			0
Inventories			0
Prepaid expenses and other current assets			0
Total current assets			0
Other			0
Total assets			0
Current portion of long-term related party payable			0
Accounts payable			0
Accrued expenses			0
Income taxes			(228)
Total current liabilities			(228)
Long-term related party payable			0
Deferred taxes			(1,359)
Other			0
Total liabilities			(1,587)
Accumulated deficit			1,587
Total shareholders' equity			1,587
Total liabilities and shareholders' equity			0
(c) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			0
Inventories		$ 489	(489)
Prepaid expenses and other current assets			0
Total current assets			(489)
Other			0
Total assets			(489)
Current portion of long-term related party payable			0
Accounts payable			0
Accrued expenses			0
Income taxes			(171)
Total current liabilities			(171)
Long-term related party payable			0
Deferred taxes			0
Other			0
Total liabilities			(171)
Accumulated deficit			(318)
Total shareholders' equity			(318)
Total liabilities and shareholders' equity			(489)
(d) \| Correction of Immaterial Errors
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accounts receivable			0
Inventories			0
Prepaid expenses and other current assets			0
Total current assets			0
Other			0
Total assets			0
Current portion of long-term related party payable			(3,410)
Accounts payable			0
Accrued expenses			0
Income taxes			0
Total current liabilities			(3,410)
Long-term related party payable			3,410
Deferred taxes			0
Other			0
Total liabilities			0
Accumulated deficit			0
Total shareholders' equity			0
Total liabilities and shareholders' equity			$ 0

Summary of Significant Accounting Policies - Restatement and Reclassification Narrative (Details) - USD ($) $ in Thousands	3 Months Ended				12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax provision (benefit)					$ 31,558	$ 35,907	$ (644)
Total revenues					150,246	173,009	14,975
Inventories	$ 3,666				3,258	3,666
Current portion of long-term related party payable	25,204				$ 34,177	25,204
Correction of Immaterial Errors \| (a)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax provision (benefit)	434	$ (863)	$ (292)	$ (866)		(1,587)
Total revenues						0
Inventories	0					0
Current portion of long-term related party payable	0					0
Correction of Immaterial Errors \| (b)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax provision (benefit)						(70)	70
Total revenues				200		(200)	200
Correction of Immaterial Errors \| (c)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax provision (benefit)						(171)
Total revenues						0
Inventories	(489)					(489)				$ 489
Current portion of long-term related party payable	0					0
Correction of Immaterial Errors \| (d)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Inventories	0					0
Current portion of long-term related party payable	(3,410)					$ (3,410)
Correction of Immaterial Errors \| (f)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income tax provision (benefit)	$ (2,606)	$ (750)	$ (1,026)	$ (830)			693	$ (333)	$ (360)
Total revenues							$ 0

Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)	12 Months Ended
	Dec. 31, 2016
Laboratory equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	P8Y
Laboratory equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	P4Y
Office and computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	P3Y
Furniture, fixtures and fittings \| Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	P10Y
Furniture, fixtures and fittings \| Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful lives	P5Y

Summary of Significant Accounting Policies - Revenue (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Change in Accounting Estimate [Line Items]
Product sales and services	$ 147,222	$ 172,288	$ 12,193
Effect on earnings per diluted share (in usd per share)	$ (1.00)	$ 0.96	$ (2.47)
License and research revenue	$ 3,024	$ 721	$ 2,782
Change in Accounting Method Accounted for as Change in Estimate
Change in Accounting Estimate [Line Items]
Product sales and services	$ 5,981
Effect on earnings per diluted share (in usd per share)	$ 0.05

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

Summary of Significant Accounting Policies - Narrative (Details)	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 € / shares shares	Dec. 31, 2015 $ / shares shares
Accounting Policies [Abstract]
Historical Revenue Percentage	50.00%
Class of Stock [Line Items]
Authorized share capital	$ 5,500,000
Ordinary shares, shares authorized (in shares) \| shares	500,000,000	53,178,000	53,178,000
Ordinary shares, nominal value (in usd or euro per share) \| (per share)	$ 0.01	€ 0.122
Preferred shares, shares authorized (in shares) \| shares	50,000,000	0	0
Preferred shares, nominal value (in usd per share) \| $ / shares	$ 0.01		$ 0
Cross-border merger nominal value adjustment	$ 0
Ordinary Shares
Class of Stock [Line Items]
Cross-border merger nominal value adjustment	(5,937,000)
Additional Paid-in Capital
Class of Stock [Line Items]
Cross-border merger nominal value adjustment	$ 5,937,000

Effect of New Accounting Standards (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Changes and Error Corrections [Abstract]
Income tax deferred charge	$ 10,342	$ 11,581	$ 13,102

Fair Value Measurements - Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	$ 114,980	$ 79,738
Long-term related party payable	135,170	97,489
Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	4,033	3,525
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		13,641
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	57,348	42,139
Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	42,814	13,738
Government securities - Non-U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	233	1,063
Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	10,471	3,992
Other securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	81	1,640
Fair Value Measurements, Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	4,033	3,525
Fair Value Measurements, Recurring \| Level 1 \| Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	4,033	3,525
Fair Value Measurements, Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	110,947	76,213
Fair Value Measurements, Recurring \| Level 2 \| Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities		13,641
Fair Value Measurements, Recurring \| Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	57,348	42,139
Fair Value Measurements, Recurring \| Level 2 \| Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	42,814	13,738
Fair Value Measurements, Recurring \| Level 2 \| Government securities - Non-U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	233	1,063
Fair Value Measurements, Recurring \| Level 2 \| Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	10,471	3,992
Fair Value Measurements, Recurring \| Level 2 \| Other securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	81	1,640
Fair Value Measurements, Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term related party payable	169,347	122,693
Total liabilities	$ 169,347	$ 122,693

Marketable Securities - Summary of Marketable Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	$ 115,218,000	$ 79,885,000
Unrealized Gains	1,234,000	1,561,000
Unrealized Losses	(1,472,000)	(1,708,000)
Fair Value	114,980,000	79,738,000
Gross realized gain	1,265,000	241	$ 24
Gross realized loss	586,000	677	$ 81
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	3,689,000	3,510,000
Unrealized Gains	409,000	29,000
Unrealized Losses	(65,000)	(14,000)
Fair Value	4,033,000	3,525,000
Time deposits
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost		13,641,000
Unrealized Gains		0
Unrealized Losses		0
Fair Value		13,641,000
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	57,871,000	42,129,000
Unrealized Gains	89,000	1,520,000
Unrealized Losses	(612,000)	(1,510,000)
Fair Value	57,348,000	42,139,000
Government securities - U.S.
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	43,049,000	13,822,000
Unrealized Gains	515,000	4,000
Unrealized Losses	(750,000)	(88,000)
Fair Value	42,814,000	13,738,000
Government securities - Non-U.S.
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	247,000	1,112,000
Unrealized Gains	0	8,000
Unrealized Losses	(14,000)	(57,000)
Fair Value	233,000	1,063,000
Other fixed-income securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	10,281,000	4,008,000
Unrealized Gains	221,000	0
Unrealized Losses	(31,000)	(16,000)
Fair Value	10,471,000	3,992,000
Other securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	81,000	1,663,000
Unrealized Gains	0	0
Unrealized Losses	0	(23,000)
Fair Value	$ 81,000	$ 1,640,000

Marketable Securities - Schedule of Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	$ 18,305
1-5 Years	80,794
5-10 Years	9,414
5-10 Years	6,467
Fair Value	114,980	$ 79,738
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	4,033
1-5 Years	0
5-10 Years	0
5-10 Years	0
Fair Value	4,033	3,525
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	11,933
1-5 Years	39,325
5-10 Years	5,655
5-10 Years	435
Fair Value	57,348	42,139
Government securities - U.S.
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	2,258
1-5 Years	33,270
5-10 Years	1,530
5-10 Years	5,756
Fair Value	42,814	13,738
Government securities - Non-U.S.
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	0
1-5 Years	0
5-10 Years	233
5-10 Years	0
Fair Value	233	1,063
Other fixed-income securities
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	0
1-5 Years	8,199
5-10 Years	1,996
5-10 Years	276
Fair Value	10,471	3,992
Other securities
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	81
1-5 Years	0
5-10 Years	0
5-10 Years	0
Fair Value	$ 81	$ 1,640

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventory reserves	$ 3,223	$ 806
Finished goods	2,429	2,545
Raw materials	829	1,121
Total	$ 3,258	$ 3,666

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Less - accumulated depreciation	$ (12,457)	$ (14,630)
Property and equipment, net	3,320	2,616
Depreciation	601	568	$ 681
Laboratory equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	9,019	9,963
Office and computer equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	2,519	2,968
Furniture, fixtures and fittings
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 4,239	$ 4,315

Acquisitions - Purchase Price Allocation (Details) - FSC $ in Thousands	Feb. 05, 2016 USD ($)
Business Acquisition [Line Items]
Accounts receivable	$ 142
Inventories	1,135
Prepaid expenses and other current assets	1,712
Deferred tax assets	853
Other assets	277
Accounts payable and other liabilities	(3,827)
Total	21,192
Marketing Rights
Business Acquisition [Line Items]
Intangible assets	16,600
Developed Technology
Business Acquisition [Line Items]
Intangible assets	$ 4,300

Acquisitions - Pro Forma Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Business Combinations [Abstract]
Net revenues	$ 150,721	$ 178,104
Net income (loss)	$ (42,290)	$ 30,965

Acquisitions (Details Textual) - USD ($) $ in Thousands		1 Months Ended			12 Months Ended
Acquisitions (Details Textual) - USD ($) $ in Thousands	Feb. 05, 2016	Feb. 29, 2016	Dec. 31, 2013	Feb. 28, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Combination, Separately Recognized Transactions [Line Items]
Payments to acquire businesses, gross					$ 30,838	$ 27,897	$ 11,936
Percentage of royalty payable on net sales			0.834%
Deerfield CSF LLC \| Affiliated Entity
Business Combination, Separately Recognized Transactions [Line Items]
Percentage of royalty payable on net sales				1.75%
FSC
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, consideration transferred	$ 21,659
Payment for settlement of net working capital	$ 467
Business combination, pro forma information, revenue of acquiree since acquisition date, actual					5,985
Business combination, pro forma information, loss of acquiree since acquisition date, actual					$ 5,839
FSC \| Maximum
Business Combination, Separately Recognized Transactions [Line Items]
Acquired intangible assets useful life	15 years
FSC \| Minimum
Business Combination, Separately Recognized Transactions [Line Items]
Acquired intangible assets useful life	9 years
FSC \| Deerfield CSF LLC \| Affiliated Entity
Business Combination, Separately Recognized Transactions [Line Items]
Business combination, recognized identifiable assets acquired and liabilities assumed, noncurrent liabilities, long-term debt	$ 15,000
Payments to acquire businesses, gross	$ 1,050	$ 1,050
Debt instrument, term	5 years	5 years
Business combination, contingent consideration, liability	$ 6,659
Percentage of royalty payable on net sales	15.00%	15.00%
FSC \| Deerfield CSF LLC \| Affiliated Entity \| Maximum
Business Combination, Separately Recognized Transactions [Line Items]
Royalty guarantees, commitments, amount	$ 12,500
Royalty guarantees, commitments, term	10 years	10 years

Goodwill and Intangible Assets - Net Book Value (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Amortizable intangible assets:
Amortizable intangible assets: Gross Value	$ 68,209	$ 47,309
Amortizable intangible assets: Accumulated Amortization	(45,372)	(31,484)
Amortizable intangible assets: Net Book Value	22,837	15,825
Unamortizable intangible assets:
Unamortizable intangible assets: Goodwill, Gross Value	18,491	18,491
Unamortizable intangible assets: Accumulated Amortization	0	0
Unamortizable intangible assets: Net Book Value	18,491	18,491
In Process Research and Development \| Bloxiverz
Amortizable intangible assets:
Amortizable intangible assets: Gross Value	35,248	35,248
Amortizable intangible assets: Accumulated Amortization	(35,248)	(23,498)
Amortizable intangible assets: Net Book Value	0	11,750
In Process Research and Development \| Vazculep
Amortizable intangible assets:
Amortizable intangible assets: Gross Value	12,061	12,061
Amortizable intangible assets: Accumulated Amortization	(8,801)	(7,986)
Amortizable intangible assets: Net Book Value	3,260	4,075
Marketing Rights
Amortizable intangible assets:
Amortizable intangible assets: Gross Value	16,600	0
Amortizable intangible assets: Accumulated Amortization	(1,019)	0
Amortizable intangible assets: Net Book Value	15,581	0
Developed Technology
Amortizable intangible assets:
Amortizable intangible assets: Gross Value	4,300	0
Amortizable intangible assets: Accumulated Amortization	(304)	0
Amortizable intangible assets: Net Book Value	$ 3,996	$ 0

Goodwill and Intangible Assets - Estimate Future Amortization (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2017	$ 2,258
2018	2,258
2019	2,258
2020	2,258
2021	$ 1,443

Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Intangible asset amortization	$ 13,888	$ 12,564	$ 11,749
Maximum
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, useful life (in years)	15 years
Minimum
Finite-Lived Intangible Assets [Line Items]
Amortizable intangible assets, useful life (in years)	3 years

Long-Term Debt (Details Textual) - USD ($) $ in Thousands	12 Months Ended
Long-Term Debt (Details Textual) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of Capitalization, Long-term Debt [Line Items]
Repayments of loans	$ 277	$ 747	$ 355
Research and development arrangement, waiver of loan repayment		1,498
French Ministry Of Research
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from loans or conditional grants	$ 815	$ 1,118

Long-Term Related Party Payable - Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Long-Term Related Party Payable
Related party payable, beginning balance	$ 122,693	$ 114,750	$ 65,670
Additions	21,659
Payments to Related Parties	(30,838)	(27,897)	(11,936)
Changes in Fair Value of Related Party Payable, Operating Expenses	49,285	30,957	57,491
Changes in Fair Value of Related Party Payable, Other Expenses	6,548
Related party payable, ending balance	169,347	122,693	$ 114,750
Less: current portion	(34,177)	(25,204)
Total long-term related party payable	135,170	97,489
Financing-related:
Long-Term Related Party Payable
Related party payable, beginning balance	0
Additions	15,000
Payments to Related Parties	0
Changes in Fair Value of Related Party Payable, Operating Expenses	0
Changes in Fair Value of Related Party Payable, Other Expenses	0
Related party payable, ending balance	15,000	0
Warrant \| Acquisition-related:
Long-Term Related Party Payable
Related party payable, beginning balance	20,617
Additions	0
Payments to Related Parties	0
Changes in Fair Value of Related Party Payable, Operating Expenses	(9,400)
Changes in Fair Value of Related Party Payable, Other Expenses	0
Related party payable, ending balance	11,217	20,617
Earn-out payments \| Acquisition-related:
Long-Term Related Party Payable
Related party payable, beginning balance	90,468
Additions	0
Payments to Related Parties	(26,700)
Changes in Fair Value of Related Party Payable, Operating Expenses	57,609
Changes in Fair Value of Related Party Payable, Other Expenses	0
Related party payable, ending balance	121,377	90,468
Royalty agreement - FSC \| Acquisition-related:
Long-Term Related Party Payable
Related party payable, beginning balance	0
Additions	6,659
Payments to Related Parties	(444)
Changes in Fair Value of Related Party Payable, Operating Expenses	1,076
Changes in Fair Value of Related Party Payable, Other Expenses	0
Related party payable, ending balance	7,291	0
Royalty agreement - Deerfield \| Financing-related:
Long-Term Related Party Payable
Related party payable, beginning balance	7,862
Additions	0
Payments to Related Parties	(2,501)
Changes in Fair Value of Related Party Payable, Operating Expenses	0
Changes in Fair Value of Related Party Payable, Other Expenses	4,433
Related party payable, ending balance	9,794	7,862
Royalty agreement - Broadfin \| Financing-related:
Long-Term Related Party Payable
Related party payable, beginning balance	3,746
Additions	0
Payments to Related Parties	(1,193)
Changes in Fair Value of Related Party Payable, Operating Expenses	0
Changes in Fair Value of Related Party Payable, Other Expenses	2,115
Related party payable, ending balance	$ 4,668	$ 3,746

Long-Term Related Party Payable - Warrant Fair Value Assumptions (Details) - Warrant - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
Weighted average exercise price per share	$ 8.63	$ 8.63
Expected term (years)	1 year 3 months	2 years 3 months
Expected volatility	54.20%	64.54%
Risk-free interest rate	0.94%	0.93%
Expected dividend yield	0.00%	0.00%

Long-Term Related Party Payable - Payable Balance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Related party payable	$ 169,347	$ 122,693	$ 114,750	$ 65,670
Payments to Related Parties	(30,838)	(27,897)	(11,936)
Fair value adjustments	55,833	$ 35,840	$ 61,016
Additions	$ 21,659

Long-Term Related Party Payable (Details Textual) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended					12 Months Ended
	Feb. 05, 2016	Mar. 13, 2012	Jan. 31, 2021	Feb. 29, 2016	Dec. 31, 2013	Feb. 28, 2013	Mar. 31, 2012	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Number of securities called by each warrant (in shares)								1
Percentage of royalty payable on net sales					0.834%
Cash consideration received on royalty agreement					$ 2,200
Payments to acquire businesses, gross								$ 30,838	$ 27,897	$ 11,936
Maximum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								22.00%
Minimum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								15.00%
Affiliated Entity \| Deerfield CSF LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales						1.75%
Cash consideration received on royalty agreement						$ 2,600
Eclat Pharmaceuticals
Line of Credit Facility [Line Items]
Warrants issued		2						2	2
Warrant term		6 years
Number of securities called by warrants (in shares)		3,300,000						3,300,000	3,300,000
Number of securities called by each warrant (in shares)		1,100,000
Exercise price of warrants (in usd per share)		$ 11.00
Percentage of earn-out payments							20.00%
Eclat Pharmaceuticals \| Exercise Price 1
Line of Credit Facility [Line Items]
Number of securities called by each warrant (in shares)		2,200,000
Exercise price of warrants (in usd per share)		$ 7.44
FSC \| Affiliated Entity \| Deerfield CSF LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales	15.00%			15.00%
Royalty amount				$ 12,500
Payments to acquire businesses, gross	$ 1,050			$ 1,050
Debt instrument, term	5 years			5 years
FSC \| Affiliated Entity \| Deerfield CSF LLC \| Scenario, Forecast
Line of Credit Facility [Line Items]
Final payments to acquire business gross			$ 15,000
FSC \| Affiliated Entity \| Deerfield CSF LLC \| Maximum
Line of Credit Facility [Line Items]
Royalty guarantees, commitments, term	10 years			10 years

Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Income (loss) before income taxes	$ (9,718)	$ 77,705	$ (90,131)
Ireland
Income Taxes [Line Items]
Income (loss) before income taxes	(22,866)	(29,469)	0
United States
Income Taxes [Line Items]
Income (loss) before income taxes	32,786	100,552	(89,739)
France
Income Taxes [Line Items]
Income (loss) before income taxes	$ (19,638)	$ 6,622	$ (392)

Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current:
United States - Federal	$ 30,738	$ 33,289	$ 0
United States - State	1,081	970	0
France	5,267	1,657	1,400
Total current	37,086	35,916	1,400
Deferred:
United States - Federal	(6,443)	504	(1,713)
United States - State	(23)	1,234	(331)
France	938	(1,747)	0
Total deferred	(5,528)	(9)	(2,044)
Income tax provision (benefit)	$ 31,558	$ 35,907	$ (644)

Income Taxes - Reconciliation of Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate	12.50%	33.30%	33.30%
Non-deductible changes in fair value of contingent consideration	(165.00%)	11.90%	(24.80%)
Change in valuation allowance	11.80%	(9.60%)	5.30%
Income tax deferred charge	(9.70%)	1.30%	(16.90%)
International tax rates differential	(31.90%)	11.00%	6.70%
Nondeductible stock based compensation	(14.80%)	1.30%	(0.80%)
Cross-border merger	(100.60%)	0.00%	0.00%
Unrecognized tax benefit	(15.20%)	0.40%	0.00%
State and local taxes (net of federal)	(9.60%)	1.50%	0.30%
Other	(2.30%)	(4.90%)	(2.30%)
Effective income tax rate	(324.80%)	46.20%	0.80%
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax provision (benefit) - at statutory tax rate	$ (1,215)	$ 25,876	$ (30,013)
Non-deductible changes in fair value of contingent consideration	16,036	9,249	22,326
Change in valuation allowance	(1,143)	(7,425)	(4,732)
Income tax deferred charge	938	980	15,273
International tax rates differential	3,097	8,547	(6,023)
Nondeductible stock based compensation	1,436	1,004	693
Cross-border merger	9,773	0	0
Unrecognized tax benefit	1,475	290	0
State and local taxes (net of federal)	934	1,170	(228)
Other	227	(3,784)	2,060
Income tax provision (benefit)	$ 31,558	$ 35,907	$ (644)

Income Taxes - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Unrecognized Tax Benefit Activity [Roll Forward]
Beginning balance	$ 448	$ 0	$ 0
Additions based on tax positions related to the current year	1,578	448	0
Additions (reductions) for tax positions of prior years	(340)	0	0
Statute of limitations expiration	0	0	0
Settlements	0	0	0
Ending balance	$ 1,686	$ 448	$ 0

Income Taxes - Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 11,566	$ 44,587
Stock based compensation	5,012	1,767
Fair value royalty agreements	3,386	2,435
Fair value contingent consideration	2,152	1,348
Other	583	1,037
Total deferred tax assets	22,699	51,174
Valuation allowances	(7,599)	(45,516)
Net deferred tax assets	15,100	5,658
Deferred tax liabilities:
Amortization	(4,349)	(5,649)
Accounts receivable	(3,319)	0
Total deferred tax liabilities	(7,668)	(5,649)
Net deferred tax assets	$ 7,432	$ 9

Income Taxes (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
Income Taxes (Details Textual) - USD ($)	Mar. 08, 2017	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Taxes [Line Items]
Statutory tax rate			12.50%	33.30%	33.30%
Increase (decrease) in income tax provision			$ (4,349,000)	$ 36,551,000
Income tax provision effect of cross-border merger			9,773,000	0	$ 0
Income tax provision effect of transfer of intellectual property			938,000	980,000	15,273,000
Reasonably possible change in amount of unrecorded benefit in next twelve months			250,000
Reasonably possible change in amount of interest and penalties in next twelve months			50,000
Unrecognized tax benefits that would impact effective tax rate		$ 0	1,565,000	291,000	0
Income tax penalties and interest expense			26,000	0	0
Income tax penalties and interest accrued			27,000	0
Deferred tax assets, tax credit carryforwards, research			1,775,000	2,382,000
Gross research tax credit			3,376,000	3,720,000
Research tax credit utilized			4,001,000
Current deferred tax liabilities			1,601,000	1,338,000
Income tax charge			31,558,000	35,907,000	(644,000)
Tax-related prepaid expenses		986,000	814,000	842,000	986,000
Deferred tax assets		$ 13,102,000	10,342,000	11,581,000	$ 13,102,000
Income tax deferred charge			11,156,000
Deferred tax amortized rate		7.00%
Income tax provision related to cross-border merger			$ 4,001,000
Subsequent Event
Income Taxes [Line Items]
Potential income tax benefit based on impact of ruling	$ 3,848,000
Potential research and development tax credit based on impact of ruling	2,582,000
Potential release of unrecognized tax benefits based on impact of ruling	$ 1,266,000
Ireland
Income Taxes [Line Items]
Statutory tax rate			12.50%
Net operating loss carryforwards			$ 45,907,000
Net operating loss carryforwards valuation allowance			5,738,000	$ 3,628,000
Tax relief amount			8,500,000
France
Income Taxes [Line Items]
Statutory tax rate				33.30%	33.30%
Net operating loss carryforwards valuation allowance				$ 40,959,000
Income tax charge		$ 14,088,000
Removal of operating loss carryforwards			111,495,000
United States
Income Taxes [Line Items]
Net operating loss carryforwards			14,920,000
Net operating loss carryforwards valuation allowance			$ 1,272,000

Post-Retirement Benefit Plans - Benefit Obligation Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Compensation rate increase	3.00%	3.00%	3.00%
Discount rate	1.31%	2.03%	1.49%
Employee turn-over	Actuarial standard and average of the last 5 years	Actuarial standard and average of the last 5 years	Actuarial standard and average of the last 5 years
Employee turn-over, average years	5 years	5 years	5 years
Average age of retirement	60 to 65 years actuarial standard based on age and professional status	60 to 65 years actuarial standard based on age and professional status	60 to 65 years actuarial standard based on age and professional status
Minimum
Defined Benefit Plan Disclosure [Line Items]
Average age of retirement, in years	60 years	60 years	60 years
Maximum
Defined Benefit Plan Disclosure [Line Items]
Average age of retirement, in years	65 years	65 years	65 years

Post-Retirement Benefit Plans - Benefit Obligation Activity (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Retirement indemnity benefit obligation, beginning of year	$ 2,170	$ 2,350
Service cost	123	117
Interest cost	29	20
Benefits paid	0	(46)
Actuarial loss (gain)	203	(27)
Exchange rate changes	(94)	(244)
Retirement indemnity benefit obligation, end of year	$ 2,431	$ 2,170

Post-Retirement Benefit Plans - Future Obligation (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Compensation and Retirement Disclosure [Abstract]
Defined Benefit Plan, Expected Future Benefit Payments, 2017	$ 0
Defined Benefit Plan, Expected Future Benefit Payments, 2018	0
Defined Benefit Plan, Expected Future Benefit Payments, 2019	11
Defined Benefit Plan, Expected Future Benefit Payments, 2020	0
Defined Benefit Plan, Expected Future Benefit Payments, 2021	0
Defined Benefit Plan, Expected Future Benefit Payments, Next five years	1,061
Defined Benefit Plan, Expected Future Benefit Payments	$ 1,072

Post-Retirement Benefit Plans (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Defined contribution plan, cost recognized	$ 348	$ 573	$ 719

Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Valued-added tax recoverable	$ 736	$ 1,099
Prepaid expenses	3,442	2,921
Advance to suppliers and other current assets	1,265	518
Income tax receivable	451	3,526
Total	$ 5,894	$ 8,064

Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Deferred tax assets	$ 7,432	$ 9
Other	99	158
Total	$ 7,531	$ 167

Other Assets and Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Other Liabilities Disclosure [Abstract]
Accrued compensation	$ 3,291	$ 1,888
Accrued social charges	794	1,710
Customer allowances	7,981	5,710
Accrued contract research organization	1,764	0
Other	3,392	0
Total	$ 17,222	$ 9,308

Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Provision for retirement indemnity	$ 2,431	$ 2,170	$ 2,350
Customer allowances	905	0
Unrecognized tax benefits	1,565	291	$ 0
Other	374	65
Total	$ 5,275	$ 2,526

Contingent Liabilities and Commitments - Purchase Commitments (Details) - Inventories $ in Thousands	Dec. 31, 2016 USD ($)
Purchase Commitment:
2017	$ 778
2018	1,032
2019	1,126
2020	1,126
2021	1,126
Thereafter	15,295
Total	$ 20,483

Contingent Liabilities and Commitments - Lease Commitments (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Lease Commitment:
2017	$ 1,117
2018	783
2019	717
2020	699
2021	441
Thereafter	600
Total	$ 4,357

Contingent Liabilities and Commitments Contingent Liabilities and Commitments - Contractual Obligations (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Long-term debt
Total	$ 815
Less than 1 Year	268
1 to 3 Years	547
3 to 5 Years	0
More than 5 Years	0
Long-term related party payable (undiscounted)
Total	278,236
Less than 1 Year	35,226
1 to 3 Years	57,466
3 to 5 Years	60,587
More than 5 Years	124,957
Purchase commitments
Total	41,721
Less than 1 Year	12,266
1 to 3 Years	11,908
3 to 5 Years	2,252
More than 5 Years	15,295
Operating leases
Total	4,982
Less than 1 Year	1,390
1 to 3 Years	1,837
3 to 5 Years	1,155
More than 5 Years	600
Total contractual cash obligations
Total	325,754
Less than 1 Year	49,150
1 to 3 Years	71,758
3 to 5 Years	63,994
More than 5 Years	$ 140,852

Contingent Liabilities and Commitments (Details Textual) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
	Aug. 01, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies [Line Items]
Commitments to purchase services		$ 22,500	$ 22,500
Operating leases, rent expense, net			970	$ 752	$ 844
Recipharm AB
Commitments And Contingencies [Line Items]
Commitments to purchase services					$ 22,500
Purchase commitment, period					5 years
Inventories \| Contract Manufacturer A
Commitments And Contingencies [Line Items]
Purchase commitment, amount			$ 7,238
Purchase commitment, period			1 year
Inventories \| Contract Manufacturer B
Commitments And Contingencies [Line Items]
Purchase commitment, period	20 years

Equity Instruments and Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 14,679	$ 7,741	$ 2,894
Cost of products and services sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	0	0	38
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	3,523	1,587	1,027
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 11,156	$ 6,154	$ 1,829

Equity Instruments and Stock Based Compensation - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	2 years 6 months	2 years 6 months	2 years 6 months
Expected volatility	60.57%	55.00%	58.00%
Risk-free interest rate	0.82%	0.89%	0.75%
Expected dividend yield	0.00%	0.00%	0.00%
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Expected volatility	58.39%	58.59%	59.00%
Risk-free interest rate	2.04%	1.89%	1.79%
Expected dividend yield	0.00%	0.00%	0.00%

Equity Instruments and Stock Based Compensation - Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Stock Options, Outstanding [Roll Forward]
Stock options outstanding, beginning balance (in shares) \| shares	2,326
Granted (in shares) \| shares	1,505
Exercised (in shares) \| shares	(15)
Forfeited (in shares) \| shares	(6)
Expired (in shares) \| shares	(78)
Stock options outstanding, ending balance (in shares) \| shares	3,732
Stock options exercisable (in shares) \| shares	1,161
Stock Options, Outstanding, Weighted Average Exercise Price [Abstract]
Stock options outstanding, beginning balance (in usd per share) \| $ / shares	$ 13.84
Granted (in usd per share) \| $ / shares	10.68
Exercised (in usd per share) \| $ / shares	6.50
Forfeited (in usd per share) \| $ / shares	14.35
Expired (in usd per share) \| $ / shares	31.70
Stock options outstanding, ending balance (in usd per share) \| $ / shares	12.07
Stock options exercisable (in usd per share) \| $ / shares	$ 10.49
Stock options outstanding, Weighted Average Remaining Contractual Life (years)	8 years 5 months 22 days
Stock options exercisable, Weighted Average Remaining Contractual Life (years)	6 years 9 months 2 days
Stock options outstanding, Aggregate Intrinsic Value \| $	$ 3,681
Stock options exercisable, Aggregate Intrinsic Value \| $	$ 3,035

Equity Instruments and Stock Based Compensation - Warrants (Details) - Warrant $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares
Warrant Activity and Other Data, Outstanding [Roll Forward]
Outstanding, beginning balance (in shares) \| shares	668
Granted (in shares) \| shares	291
Exercised (in shares) \| shares	0
Forfeited (in shares) \| shares	0
Expired (in shares) \| shares	0
Outstanding, ending balance (in shares) \| shares	959
Warrants exercisable (in shares) \| shares	668
Warrant Activity and Other Data, Weighted Average Exercise Price [Abstract]
Warrants outstanding, beginning balance (in usd per share) \| $ / shares	$ 16.97
Granted (in usd per share) \| $ / shares	13.59
Exercised (in usd per share) \| $ / shares	0.00
Forfeited (in usd per share) \| $ / shares	0.00
Expired (in usd per share) \| $ / shares	0.00
Warrants outstanding, ending balance (in usd per share) \| $ / shares	16.05
Warrants exercisable (in usd per share) \| $ / shares	$ 17.12
Warrants outstanding, Weighted Average Remaining Contractual Life (years)	2 years 5 months 20 days
Warrants exercisable, Weighted Average Remaining Contractual Life (years)	1 year 11 months 20 days
Warrants outstanding, Aggregate Intrinsic Value \| $	$ 276
Warrants exercisable, Aggregate Intrinsic Value \| $	$ 276

Equity Instruments and Stock Based Compensation - Free Share Awards (Details) - Free Share Award - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Free Share Activity and Other Data, Nonvested [Roll Forward]
Outstanding, beginning balance (in shares)	226
Granted (in shares)	463	0
Vested (in shares)	(115)
Forfeited (in shares)	(1)
Outstanding, ending balance (in shares)	573	226
Free Share Activity and Other Data, Weighted Average Grant Date Fair Value [Abstract]
Nonvested free share award, beginning balance (in usd per share)	$ 13.95
Granted (in usd per share)	12.11		$ 16.30
Vested (in usd per share)	13.44
Forfeited (in usd per share)	16.27
Nonvested free share award, ending balance (in usd per share)	$ 12.57	$ 13.95

Equity Instruments and Stock Based Compensation (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2014 USD ($) $ / shares	Dec. 31, 2015 € / shares	Dec. 31, 2015 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense \| $	$ 12,874
Weighted average period for unrecognized expense	3.2 years
Excess tax benefit related to stock-based compensation \| $	$ 65	$ 1,767
Ordinary shares, shares authorized (in shares)	500,000,000				53,178,000
Ordinary shares, nominal value (in usd or euro per share) \| (per share)	$ 0.01			€ 0.122
Ordinary shares, shares issued (in shares)	41,371,000				41,241,000
Ordinary shares, shares outstanding (in shares)	41,371,000				41,241,000
Preferred shares, shares authorized (in shares)	50,000,000				0
Preferred shares, nominal value (in usd per share) \| $ / shares	$ 0.01				$ 0
Aggregate intrinsic value of options exercised \| $	$ 58	$ 10,063	$ 3,789
Grant date fair value of options granted (in usd per share) \| $ / shares	$ 6.14	$ 9.38	$ 9.19
Number of securities called by each warrant (in shares)	1
Aggregate intrinsic value of warrants exercised \| $	$ 0		$ 3,107		$ 2,698
Grant date fair value of warrants granted (in usd per share) \| $ / shares	$ 2.99	$ 5.92	$ 3.90
Additional warrants outstanding	3,300,000
Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	1 year
Expiration period (in years)	4 years
Number of shares authorized (in shares)	59,000
Free Share Award
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)		4 years
Holding period (in years)	2 years
Number of shares authorized (in shares)	290,000
Weighted average grant fair value of free share awards \| $ / shares	$ 12.11		$ 16.30
Free Share Award \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period (in years)		2 years
Free Share Award \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period (in years)		4 years
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period (in years)	4 years
Expiration period (in years)	10 years
Number of shares authorized (in shares)	94,000

Earnings (Loss) Per Share - Reconciliation of basic and diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net income (loss):
Net income (loss) from continuing operations	$ (41,276,000)	$ 41,798,000	$ (89,487,000)
Net income (loss) from discontinued operations	0	0	4,018,000
Net income (loss)	$ (41,276,000)	$ 41,798,000	$ (85,469,000)
Weighted average shares:
Basic shares (in shares)	41,248	40,580	36,214
Effect of dilutive securities - options and warrants outstanding (in shares)	0	3,039	0
Diluted shares (in shares)	41,248	43,619	36,214
Earnings (loss) per share - basic:
Continuing operations (in usd per share)	$ (1.00)	$ 1.03	$ (2.47)
Discontinued operations (in usd per share)	0.00	0.00	0.11
Net income (loss) per share - basic (in usd per share)	(1.00)	1.03	(2.36)
Earnings (loss) per share - diluted:
Continuing operations (in usd per share)	(1.00)	0.96	(2.47)
Discontinued operations (in usd per share)	0.00	0.00	0.11
Net income (loss) per share - diluted (in usd per share)	$ (1.00)	$ 0.96	$ (2.36)

Earnings (Loss) Per Share (Details Textual) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share	8,564	635	6,753

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss)
Beginning balance	$ 69,134	$ 25,025	$ (8,819)
Net other comprehensive (loss) income	(42,184)	26,564	(103,707)
Ending balance	42,069	69,134	25,025
Foreign currency translation adjustment
Accumulated Other Comprehensive Income (Loss)
Beginning balance	(22,312)	(7,225)	10,815
Net other comprehensive (loss) income	(1,024)	(15,087)	(18,040)
Ending balance	(23,336)	(22,312)	(7,225)
Unrealized gain (loss) on marketable securities, net
Accumulated Other Comprehensive Income (Loss)
Beginning balance	(345)	(198)	0
Net other comprehensive (loss) income	116	(147)	(198)
Ending balance	(229)	(345)	(198)
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss)
Beginning balance	(22,657)	(7,423)	10,815
Ending balance	$ (23,565)	$ (22,657)	$ (7,423)

Comprehensive Income (Loss) (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Unrealized gain (loss) on marketable securities, tax	$ 16	$ (20)	$ 0

Company Operations by Product, Customer and Geographic Area - Revenue by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Total product sales and services	$ 147,222	$ 172,288	$ 12,193
License and research revenue	3,024	721	2,782
Total	150,246	173,009	14,975
Bloxiverz
Segment Reporting Information [Line Items]
Total product sales and services	82,896	150,083	10,411
Vazculep
Segment Reporting Information [Line Items]
Total product sales and services	39,796	20,151	0
Akovaz
Segment Reporting Information [Line Items]
Total product sales and services	16,831	0	0
Other
Segment Reporting Information [Line Items]
Total product sales and services	$ 7,699	$ 2,054	$ 1,782

Company Operations by Product, Customer and Geographic Area - Revenue by Significant Customer (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Total product sales and services	$ 147,222	$ 172,288	$ 12,193
License and research revenue	3,024	721	2,782
Total	150,246	173,009	14,975
Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	147,222	172,288	12,193
License and research revenue	3,024	721	2,782
Total	150,246	173,009	14,975
Customer A \| Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	51,648	53,988	3,937
Customer B \| Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	39,359	60,420	3,859
Customer C \| Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	30,916	43,434	3,563
Customer D \| Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	17,728	0	0
Other \| Wholesaler Customer
Segment Reporting Information [Line Items]
Total product sales and services	$ 7,571	$ 14,446	$ 834

Company Operations by Product, Customer and Geographic Area - Data by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue by Geographic Region:
Total	$ 150,246	$ 173,009	$ 14,975
Long-lived Assets by Geographic Region:
Long-lived assets	44,747	37,090	48,781
UNITED STATES
Revenue by Geographic Region:
Total	147,283	172,179	14,502
Long-lived Assets by Geographic Region:
Long-lived assets	42,021	34,515	47,077
FRANCE
Revenue by Geographic Region:
Total	0	89	473
Long-lived Assets by Geographic Region:
Long-lived assets	2,524	2,317	1,704
IRELAND
Revenue by Geographic Region:
Total	2,963	741	0
Long-lived Assets by Geographic Region:
Long-lived assets	$ 202	$ 258	$ 0

Company Operations by Product, Customer and Geographic Area (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($) segment	Dec. 31, 2015 USD ($)
Segment Reporting [Abstract]
Number of segments \| segment	1
Concentration Risk [Line Items]
Accounts receivable	$ 17,839	$ 7,487
Accounts Receivable \| Customer Concentration Risk \| Customer One
Concentration Risk [Line Items]
Concentration risk, percentage	42.00%
Accounts receivable	$ 7,472
Accounts Receivable \| Customer Concentration Risk \| Customer Two
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%
Accounts receivable	$ 4,307
Accounts Receivable \| Customer Concentration Risk \| Customer Three
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%
Accounts receivable	$ 4,291

Discontinued Operations - Master Agreement (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Year 1		$ 4,250
Year 2		4,250
Year 3		4,250
Year 4		4,875
Year 5		4,875
Total	$ 22,500	$ 22,500

Discontinued Operations - Option Agreement Net Income (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Revenues	$ 0	$ 0	$ 14,967,000
Operating income (loss)	0	0	(875,000)
Gain on disposal	0	0	5,007,000
Interest expense	0	0	(4,000)
Income tax provision	0	0	(110,000)
Net income from discontinued operations	$ 0	$ 0	$ 4,018,000

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Discontinued Operations - Option Agreement Cash Flow (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale - Pessac Business - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditures	$ 0	$ 0	$ 1,271,000
Depreciation and amortization	0	0	1,709,000
Operating and investing non-cash elements	$ 0	$ 0	$ (740,000)

Discontinued Operations (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
Discontinued Operations (Details Textual) - USD ($)	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Discontinued Operations [Line Items]
Gain on disposal			$ 0	$ 0	$ 5,007,000
Stock issued, value, acquisition					13,049,000
Initial noncancellable term of master agreement	5 years
Percentage of margin on costs incurred on services	20.00%
Minimum amount on supply and services of products	$ 22,500,000		22,500,000
Research and development expense			34,611,000	25,608,000	$ 17,298,000
Recipharm AB \| Equity securities
Discontinued Operations [Line Items]
Stock issued, value, acquisition	13,000,000
MSA
Discontinued Operations [Line Items]
Research and development expense			4,541,000	4,089,000
Services delivered and commitments satisfied			$ 939,000	$ 5,679,000
Discontinued Operations, Held-for-sale or Disposed of by Sale \| Pessac Business
Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	13,200,000
Contribution for potential employee obligations	$ 700,000
Gain on disposal		$ 5,007,000

Related Party Transactions (Details Textual) - USD ($) $ in Thousands				1 Months Ended					12 Months Ended
	Feb. 05, 2016	Dec. 03, 2013	Mar. 13, 2012	Jan. 31, 2021	Feb. 29, 2016	Mar. 31, 2014	Dec. 31, 2013	Feb. 28, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Payments to acquire businesses, gross									$ 30,838	$ 27,897	$ 11,936
Percentage of royalty payable on net sales							0.834%
Deerfield Debt Financing
Related Party Transaction [Line Items]
Repayments of long-term lines of credit						$ 15,000
Broadfin Debt Financing
Related Party Transaction [Line Items]
Repayments of long-term lines of credit						5,000
Senior Notes
Related Party Transaction [Line Items]
Repayments of related party debt						$ 12,000
Royalty Arrangement
Related Party Transaction [Line Items]
Long-term debt repayment percentage		0.834%						1.75%
Debt repayment term		Dec. 31, 2024						Dec. 31, 2024
Eclat Pharmaceuticals
Related Party Transaction [Line Items]
Warrants issued			2						2	2
Number of securities called by warrants (in shares)			3,300,000						3,300,000	3,300,000
Percentage of earn out payment									20.00%	20.00%
Affiliated Entity \| Deerfield CSF LLC
Related Party Transaction [Line Items]
Percentage of royalty payable on net sales								1.75%
Affiliated Entity \| Deerfield CSF LLC \| FSC
Related Party Transaction [Line Items]
Payments to acquire businesses, gross	$ 1,050				$ 1,050
Debt instrument, term	5 years				5 years
Percentage of royalty payable on net sales	15.00%				15.00%
Scenario, Forecast \| Affiliated Entity \| Deerfield CSF LLC \| FSC
Related Party Transaction [Line Items]
Final payments to acquire business gross				$ 15,000
Total payments to acquire business gross				$ 20,250
Maximum \| Affiliated Entity \| Deerfield CSF LLC \| FSC
Related Party Transaction [Line Items]
Royalty guarantees, commitments, amount	$ 12,500
Royalty guarantees, commitments, term	10 years				10 years

Subsequent Event (Details Textual)	Mar. 28, 2017 USD ($)
Subsequent Event
Subsequent Event [Line Items]
Stock repurchase program, authorized amount	$ 25,000,000

Schedule II - Valuation and Qualifying Accounts (Details) - Valuation Allowance of Deferred Tax Assets - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 45,516	$ 57,980	$ 69,939
Additions: Charges to expense	6,873	4,312	8,453
Deductions	(42,417)	(11,737)	(13,185)
Other changes	(2,373)	(5,039)	(7,227)
Balance at end of period	$ 7,599	$ 45,516	$ 57,980